BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800. [PMID: 12091876 DOI: 10.1038/nm730] [Cited by in Crossref: 2349] [Cited by in F6Publishing: 2553] [Article Influence: 117.5] [Reference Citation Analysis]
Number Citing Articles
1 Kitazawa Y, Fujino M, Wang Q, Kimura H, Azuma M, Kubo M, Abe R, Li X. Involvement of the Programmed Death-1/Programmed Death-1 Ligand Pathway in CD4+CD25+ Regulatory T-Cell Activity to Suppress Alloimmune Responses. Transplantation 2007;83:774-82. [DOI: 10.1097/01.tp.0000256293.90270.e8] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 6.3] [Reference Citation Analysis]
2 Kern R, Correa SC, Scandolara TB, Carla da Silva J, Pires BR, Panis C. Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology. Per Med 2020;17:399-420. [PMID: 32804054 DOI: 10.2217/pme-2020-0070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Niederkorn JY. Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism? Front Immunol 2012;3:148. [PMID: 22707951 DOI: 10.3389/fimmu.2012.00148] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
4 Lamarca A, Nonaka D, Breitwieser W, Ashton G, Barriuso J, McNamara MG, Moghadam S, Rogan J, Mansoor W, Hubner RA, Clark C, Chakrabarty B, Valle JW. PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. Oncotarget 2018;9:14922-38. [PMID: 29599916 DOI: 10.18632/oncotarget.24464] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
5 Lee GA, Lin WL, Kuo DP, Li YT, Chang YW, Chen YC, Huang SW, Hsu JB, Chen CY. Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide. Int J Nanomedicine 2021;16:5233-46. [PMID: 34366665 DOI: 10.2147/IJN.S310464] [Reference Citation Analysis]
6 Guo Y, Ji X, Liu J, Fan D, Zhou Q, Chen C, Wang W, Wang G, Wang H, Yuan W, Ji Z, Sun Z. Effects of exosomes on pre-metastatic niche formation in tumors. Mol Cancer. 2019;18:39. [PMID: 30857545 DOI: 10.1186/s12943-019-0995-1] [Cited by in Crossref: 104] [Cited by in F6Publishing: 114] [Article Influence: 34.7] [Reference Citation Analysis]
7 Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, Liu X, Lv Z, Yang P, Xu W, Gao W, Wu Y. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer 2021;20:126. [PMID: 34598686 DOI: 10.1186/s12943-021-01431-6] [Reference Citation Analysis]
8 Wang J, Wang Y, Steffani M, Stöß C, Ankerst D, Friess H, Hüser N, Hartmann D. Novel Risk Classification Based on Pyroptosis-Related Genes Defines Immune Microenvironment and Pharmaceutical Landscape for Hepatocellular Carcinoma. Cancers 2022;14:447. [DOI: 10.3390/cancers14020447] [Reference Citation Analysis]
9 Chang JH, Jiang Y, Pillarisetty VG. Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. Medicine (Baltimore) 2016;95:e5541. [PMID: 27930550 DOI: 10.1097/MD.0000000000005541] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 12.4] [Reference Citation Analysis]
10 Liu S, Zhang M, Zhang W. Strategies of Antigen-Specific T-Cell–Based Immunotherapy for Cancer. Cancer Biotherapy and Radiopharmaceuticals 2005;20:491-501. [DOI: 10.1089/cbr.2005.20.491] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
11 Zhang B, Wang D, Zhang X, Cui X, Kong L, Li M, Yu J. Temozolomide Combined With Capecitabine In The Treatment Of Mixed Neuroendocrine Carcinoma Of The Lung With Poor Tolerance After Repeated Radiochemotherapy: A Case Report And Literature Review. Onco Targets Ther 2019;12:9663-8. [PMID: 32009800 DOI: 10.2147/OTT.S210699] [Reference Citation Analysis]
12 Chen Y, Zhang Y, Chai X, Gao J, Chen G, Zhang W, Zhang Y. Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors. Biomed Res Int 2018;2018:5830547. [PMID: 29850538 DOI: 10.1155/2018/5830547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
13 Niederkorn JY. Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res 2009;28:329-47. [PMID: 19563908 DOI: 10.1016/j.preteyeres.2009.06.002] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
14 Gondaira S, Nishi K, Tanaka T, Yamamoto T, Nebu T, Watanabe R, Konnai S, Hayashi T, Kiku Y, Okamoto M, Matsuda K, Koiwa M, Iwano H, Nagahata H, Higuchi H. Immunosuppression in Cows following Intramammary Infusion of Mycoplasma bovis. Infect Immun 2020;88:e00521-19. [PMID: 31843962 DOI: 10.1128/IAI.00521-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wilhelm J, Quiñones-Pérez M, Wang J, Wang X, Basava VS, Gao J. Antigen folding improves loading efficiency and antitumor efficacy of PC7A nanoparticle vaccine. J Control Release 2021;329:353-60. [PMID: 33301836 DOI: 10.1016/j.jconrel.2020.11.056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Liu H, Ma Y, Yang C, Xia S, Pan Q, Zhao H, Fang W, Chen X, Zhang Y, Zou B, Li Q, Wan Y, Chen H, Tang Y, Zhao J, Weng D, Xia L, Zhang L, Xia J. Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer. Clin Transl Immunology 2020;9:e1154. [PMID: 33072320 DOI: 10.1002/cti2.1154] [Reference Citation Analysis]
17 Chen L. From the guest editor: Tumor site immune modulation therapy. Cancer J 2014;20:254-5. [PMID: 25098284 DOI: 10.1097/PPO.0000000000000062] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
18 Ferris RL, Lotze MT, Leong SP, Hoon DS, Morton DL. Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. Clin Exp Metastasis 2012;29:729-36. [PMID: 22851005 DOI: 10.1007/s10585-012-9520-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
19 Chae YK, Arya A, Chiec L, Shah H, Rosenberg A, Patel S, Raparia K, Choi J, Wainwright DA, Villaflor V. Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? Oncotarget. 2017;8:100863-100898. [PMID: 29246028 DOI: 10.18632/oncotarget.19809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
20 Liu X, Liu L, Ren Z, Yang K, Xu H, Luan Y, Fu K, Guo J, Peng H, Zhu M, Fu YX. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. Cell Rep 2018;24:2101-11. [PMID: 30134171 DOI: 10.1016/j.celrep.2018.07.062] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 21.0] [Reference Citation Analysis]
21 Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012;189:4674-83. [PMID: 23028051 DOI: 10.4049/jimmunol.1201654] [Cited by in Crossref: 162] [Cited by in F6Publishing: 148] [Article Influence: 16.2] [Reference Citation Analysis]
22 Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) 2015;7:2397-414. [PMID: 26690220 DOI: 10.3390/cancers7040900] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
23 Tripathi A, Kaymakcalan MD, LeBoeuf NR, Harshman LC. Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management. Curr Opin Urol 2016;26:548-55. [PMID: 27517638 DOI: 10.1097/MOU.0000000000000332] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
24 Pan C, Liu H, Robins E, Song W, Liu D, Li Z, Zheng L. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol 2020;13:29. [PMID: 32245497 DOI: 10.1186/s13045-020-00862-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
25 Ballesteros-Briones MC, Martisova E, Casales E, Silva-Pilipich N, Buñuales M, Galindo J, Mancheño U, Gorraiz M, Lasarte JJ, Kochan G, Escors D, Sanchez-Paulete AR, Melero I, Prieto J, Hernandez-Alcoceba R, Hervas-Stubbs S, Smerdou C. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses. Mol Ther 2019;27:1892-905. [PMID: 31563534 DOI: 10.1016/j.ymthe.2019.09.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
26 Udhwani T, Mukherjee S, Sharma K, Sweta J, Khandekar N, Nayarisseri A, Singh SK. Design of PD-L1 inhibitors for lung cancer. Bioinformation 2019;15:139-50. [PMID: 31435160 DOI: 10.6026/97320630015139] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
27 Feld E, Horn L. Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. Onco Targets Ther 2017;10:3697-708. [PMID: 28769573 DOI: 10.2147/OTT.S97903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
28 Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945-950. [PMID: 25981182 DOI: 10.1111/cas.12695] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
29 Spyrou N, Vallianou N, Kadillari J, Dalamaga M. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era. Seminars in Cancer Biology 2021;73:356-76. [DOI: 10.1016/j.semcancer.2021.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Masarova L, Bose P, Verstovsek S. The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep 2019;14:310-27. [PMID: 31228096 DOI: 10.1007/s11899-019-00527-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
31 D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, Tap WD. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 2015;46:357-65. [PMID: 25540867 DOI: 10.1016/j.humpath.2014.11.001] [Cited by in Crossref: 151] [Cited by in F6Publishing: 154] [Article Influence: 18.9] [Reference Citation Analysis]
32 Qian J, Chen T, Wu Q, Zhou L, Zhou W, Wu L, Wang S, Lu J, Wang W, Li D, Xie H, Su R, Guo D, Liu Z, He N, Yin S, Zheng S. Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8+ T cells in liver cancer. Cancer Lett 2020;495:1-11. [PMID: 32949680 DOI: 10.1016/j.canlet.2020.09.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Quatrini L, Mariotti FR, Munari E, Tumino N, Vacca P, Moretta L. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers (Basel) 2020;12:E3285. [PMID: 33172030 DOI: 10.3390/cancers12113285] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
34 Cascio MJ, Whitley EM, Sahay B, Cortes-Hinojosa G, Chang LJ, Cowart J, Salute M, Sayour E, Dark M, Sandoval Z, Mitchell DA, Milner RJ. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate. Vet Immunol Immunopathol 2021;232:110169. [PMID: 33387703 DOI: 10.1016/j.vetimm.2020.110169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Lecarpentier Y, Schussler O, Hébert JL, Vallée A. Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers. Front Oncol 2019;9:1248. [PMID: 31803621 DOI: 10.3389/fonc.2019.01248] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
36 Holets LM, Hunt JS, Petroff MG. Trophoblast CD274 (B7-H1) Is Differentially Expressed Across Gestation: Influence of Oxygen Concentration1. Biology of Reproduction 2006;74:352-8. [DOI: 10.1095/biolreprod.105.046581] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
37 Roh J, Jeon Y, Lee AN, Lee SM, Kim Y, Sung CO, Park CJ, Hong JY, Yoon DH, Suh C, Huh J, Choi I, Park CS. The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget 2017;8:58122-32. [PMID: 28938542 DOI: 10.18632/oncotarget.19468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
38 Frenel J, Le Tourneau C, O’neil B, Ott PA, Piha-paul SA, Gomez-roca C, van Brummelen EM, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. JCO 2017;35:4035-41. [DOI: 10.1200/jco.2017.74.5471] [Cited by in Crossref: 184] [Cited by in F6Publishing: 104] [Article Influence: 36.8] [Reference Citation Analysis]
39 Márquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, González-Cao M, Martín-Algarra S. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med 2015;3:267. [PMID: 26605313 DOI: 10.3978/j.issn.2305-5839.2015.10.27] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
40 Zhao Q, Xie R, Lin S, You X, Weng X. Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials. Biomed Res Int 2018;2018:3820956. [PMID: 30345301 DOI: 10.1155/2018/3820956] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
41 Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225-1235. [PMID: 18820683 DOI: 10.1038/ni.1655] [Cited by in Crossref: 445] [Cited by in F6Publishing: 426] [Article Influence: 31.8] [Reference Citation Analysis]
42 Kalim M, Iqbal Khan MS, Zhan J. Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy. Chem Biol Drug Des 2020;95:552-66. [PMID: 32166894 DOI: 10.1111/cbdd.13677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Dong H, Yan Y, Dronca RS, Markovic SN. A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. SOJ Immunol 2017;5:1-5. [PMID: 29629436 DOI: 10.15226/2372-0948/5/1/00155] [Reference Citation Analysis]
44 Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14:1212-1218. [PMID: 24240160 DOI: 10.1038/ni.2762] [Cited by in Crossref: 532] [Cited by in F6Publishing: 487] [Article Influence: 66.5] [Reference Citation Analysis]
45 Sanmamed MF, Chester C, Melero I, Kohrt H. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. Ann Oncol 2016;27:1190-8. [PMID: 26912558 DOI: 10.1093/annonc/mdw041] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 14.7] [Reference Citation Analysis]
46 Sudo A, Chihara N, Takenaka Y, Nakamura T, Ueda T, Sekiguchi K, Toda T. Paraneoplastic NMOSD associated with EG junction adenocarcinoma expressing unprotected AQP4. Neurol Neuroimmunol Neuroinflamm 2018;5:e482. [PMID: 29998158 DOI: 10.1212/NXI.0000000000000482] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
47 Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD. Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell 2018;33:1017-1032.e7. [PMID: 29894689 DOI: 10.1016/j.ccell.2018.05.009] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 23.3] [Reference Citation Analysis]
48 Jiao P, Geng Q, Jin P, Su G, Teng H, Dong J, Yan B. Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy. Curr Pharm Des 2018;24:4911-20. [PMID: 30417781 DOI: 10.2174/1381612824666181112114958] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
49 Zhou Y, Wang Y, Chen H, Xu Y, Luo Y, Deng Y, Zhang J, Shao A. Immuno-oncology: are TAM receptors in glioblastoma friends or foes? Cell Commun Signal 2021;19:11. [PMID: 33509214 DOI: 10.1186/s12964-020-00694-8] [Reference Citation Analysis]
50 Hsu ML, Naidoo J. Principles of Immunotherapy in Non-Small Cell Lung Cancer. Thorac Surg Clin 2020;30:187-98. [PMID: 32327177 DOI: 10.1016/j.thorsurg.2020.01.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Richards RM, Sotillo E, Majzner RG. CAR T Cell Therapy for Neuroblastoma. Front Immunol 2018;9:2380. [PMID: 30459759 DOI: 10.3389/fimmu.2018.02380] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
52 Penaloza-MacMaster P, Kamphorst AO, Wieland A, Araki K, Iyer SS, West EE, O'Mara L, Yang S, Konieczny BT, Sharpe AH, Freeman GJ, Rudensky AY, Ahmed R. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med. 2014;211:1905-1918. [PMID: 25113973 DOI: 10.1084/jem.20132577] [Cited by in Crossref: 134] [Cited by in F6Publishing: 131] [Article Influence: 16.8] [Reference Citation Analysis]
53 Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014;33:641-55. [PMID: 24477411 DOI: 10.1007/s10555-013-9479-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
54 Zhu X, Yang H, Lang J, Zhang Y. Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases. Eur J Obstet Gynecol Reprod Biol 2019;240:103-8. [PMID: 31242460 DOI: 10.1016/j.ejogrb.2019.06.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Martin-Orozco N, Dong C. New battlefields for costimulation. J Exp Med 2006;203:817-20. [PMID: 16606678 DOI: 10.1084/jem.20060219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
56 Miao J, Hsu PC, Yang YL, Xu Z, Dai Y, Wang Y, Chan G, Huang Z, Hu B, Li H, Jablons DM, You L. YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget 2017;8:114576-87. [PMID: 29383103 DOI: 10.18632/oncotarget.23051] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
57 Rajani KR, Vile RG. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses 2015;7:5889-901. [PMID: 26580645 DOI: 10.3390/v7112914] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
58 Prinzing BL, Gottschalk SM, Krenciute G. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? Expert Rev Anticancer Ther 2018;18:451-61. [PMID: 29533108 DOI: 10.1080/14737140.2018.1451749] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
59 Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget 2015;6:40836-49. [PMID: 26517811 DOI: 10.18632/oncotarget.5696] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 12.0] [Reference Citation Analysis]
60 Lin J, Hafrén L, Kerschner J, Li JD, Brown S, Zheng QY, Preciado D, Nakamura Y, Huang Q, Zhang Y. Panel 3: Genetics and Precision Medicine of Otitis Media. Otolaryngol Head Neck Surg 2017;156:S41-50. [PMID: 28372532 DOI: 10.1177/0194599816685559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
61 Arrieta O, Montes-Servín E, Hernandez-Martinez JM, Cardona AF, Casas-Ruiz E, Crispín JC, Motola D, Flores-Estrada D, Barrera L. Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget 2017;8:101994-2005. [PMID: 29254220 DOI: 10.18632/oncotarget.22025] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 8.4] [Reference Citation Analysis]
62 Barbey C, Baumgaertner P, Devevre E, Rubio-Godoy V, Derre L, Bricard G, Guillaume P, Luescher IF, Liénard D, Cerottini JC, Romero P, Rufer N, Speiser DE. IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. J Immunol 2007;178:3566-74. [PMID: 17339453 DOI: 10.4049/jimmunol.178.6.3566] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
63 Ehsan N, Murad S, Ashiq T, Mansoor MU, Gul S, Khalid S, Younas M. Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast. Tumour Biol 2013;34:1053-9. [PMID: 23338716 DOI: 10.1007/s13277-013-0645-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
64 Zhu X, Li S, Xu B, Luo H. Cancer evolution: A means by which tumors evade treatment. Biomed Pharmacother 2021;133:111016. [PMID: 33246226 DOI: 10.1016/j.biopha.2020.111016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
65 Jian Y, Yang K, Sun X, Zhao J, Huang K, Aldanakh A, Xu Z, Wu H, Xu Q, Zhang L, Xu C, Yang D, Wang S. Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma. Front Immunol 2021;12:639636. [PMID: 33767709 DOI: 10.3389/fimmu.2021.639636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Liu C, Lu J, Tian H, Du W, Zhao L, Feng J, Yuan D, Li Z. Increased expression of PD‑L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. Mol Med Rep 2017;15:1063-70. [PMID: 28075442 DOI: 10.3892/mmr.2017.6102] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 7.4] [Reference Citation Analysis]
67 Prud’homme GJ. Altering immune tolerance therapeutically: the power of negative thinking. Journal of Leukocyte Biology 2004;75:586-99. [DOI: 10.1189/jlb.0803394] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
68 He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep 2015;5:13110. [PMID: 26279307 DOI: 10.1038/srep13110] [Cited by in Crossref: 198] [Cited by in F6Publishing: 204] [Article Influence: 28.3] [Reference Citation Analysis]
69 Roberts J, Salaria SN, Cates J, Wang Y, Vnencak-Jones C, Berlin J, Shi C. PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes. Am J Clin Pathol 2019;152:384-91. [PMID: 31152546 DOI: 10.1093/ajcp/aqz052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
70 Loo K, Daud AI. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs. Cancer J. 2017;23:3-9. [PMID: 28114249 DOI: 10.1097/ppo.0000000000000238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
71 Wu CT, Chen WC, Chang YH, Lin WY, Chen MF. The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep. 2016;6:19740. [PMID: 26804478 DOI: 10.1038/srep19740] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 15.8] [Reference Citation Analysis]
72 Nishimori A, Konnai S, Okagawa T, Maekawa N, Ikebuchi R, Goto S, Sajiki Y, Suzuki Y, Kohara J, Ogasawara S, Kato Y, Murata S, Ohashi K. In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. PLoS One 2017;12:e0174916. [PMID: 28445479 DOI: 10.1371/journal.pone.0174916] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
73 Maisel K, Merrilees MJ, Atochina-Vasserman EN, Lian L, Obraztsova K, Rue R, Vasserman AN, Zuo N, Angel LF, Gow AJ, Kang I, Wight TN, Eruslanov E, Swartz MA, Krymskaya VP. Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2018;59:723-32. [PMID: 30095976 DOI: 10.1165/rcmb.2018-0123OC] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 6.3] [Reference Citation Analysis]
74 Zhang J, Wolfgang CL, Zheng L. Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel). 2018;10. [PMID: 29385739 DOI: 10.3390/cancers10020039] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
75 Wang X, Waschke BC, Woolaver RA, Chen Z, Zhang G, Piscopio AD, Liu X, Wang JH. Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas. Cancer Immunol Res 2019;7:1318-31. [PMID: 31235619 DOI: 10.1158/2326-6066.CIR-18-0875] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
76 Porichis F, Kaufmann DE. Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV/AIDS Rep 2012;9:81-90. [PMID: 22198819 DOI: 10.1007/s11904-011-0106-4] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 7.9] [Reference Citation Analysis]
77 Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother. 2012;61:917-926. [PMID: 22116345 DOI: 10.1007/s00262-011-1155-7] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 9.5] [Reference Citation Analysis]
78 Pardoll D. Timeline: a decade of advances in immunotherapy. Nat Med 2011;17:296. [PMID: 21383743 DOI: 10.1038/nm0311-296] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
79 Severson JJ, Serracino HS, Mateescu V, Raeburn CD, McIntyre RC, Sams SB, Haugen BR, French JD. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-630. [PMID: 25701326 DOI: 10.1158/2326-6066.cir-14-0201] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
80 Shibahara D, Tanaka K, Iwama E, Kubo N, Ota K, Azuma K, Harada T, Fujita J, Nakanishi Y, Okamoto I. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer. J Thorac Oncol 2018;13:926-37. [PMID: 29596910 DOI: 10.1016/j.jtho.2018.03.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
81 Ocaña MC, Martínez-poveda B, Quesada AR, Medina MÁ. Metabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic target. Med Res Rev 2019;39:70-113. [DOI: 10.1002/med.21511] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
82 Du Y, Nie L, Xu L, Wu X, Zhang S, Xue J. Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity. Scand J Immunol 2020;92:e12884. [PMID: 32243638 DOI: 10.1111/sji.12884] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
83 Concha-Benavente F, Ferris RL. Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Curr Opin Immunol 2017;45:52-9. [PMID: 28208102 DOI: 10.1016/j.coi.2017.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
84 Gedeon PC, Champion CD, Rhodin KE, Woroniecka K, Kemeny HR, Bramall AN, Bernstock JD, Choi BD, Sampson JH. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Rev Clin Pharmacol 2020;13:1147-58. [PMID: 32862726 DOI: 10.1080/17512433.2020.1817737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Ma Y, Qiao S, Wang Y, Lin Y, An H, Wu X, Wang L, Wang H. Nanoantagonists with nanophase-segregated surfaces for improved cancer immunotherapy. Biomaterials 2018;156:248-57. [DOI: 10.1016/j.biomaterials.2017.11.048] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
86 Yadav RK, Ali A, Kumar S, Sharma A, Baghchi B, Singh P, Das S, Singh C, Sharma S. CAR T cell therapy: newer approaches to counter resistance and cost. Heliyon 2020;6:e03779. [PMID: 32322738 DOI: 10.1016/j.heliyon.2020.e03779] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
87 Zhang Y, Xu J, Zhang N, Chen M, Wang H, Zhu D. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. Cancer Letters 2019;458:123-35. [DOI: 10.1016/j.canlet.2019.05.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
88 Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, Adamstein N, Wang X, Edwards NA, Wu T, Maric D, Giles AJ, Gilbert MR, Quezado M, Nduom EK. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma. Neurosurgery 2019;85:280-9. [PMID: 30011045 DOI: 10.1093/neuros/nyy268] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
89 Betzler AC, Theodoraki MN, Schuler PJ, Döscher J, Laban S, Hoffmann TK, Brunner C. NF-κB and Its Role in Checkpoint Control. Int J Mol Sci 2020;21:E3949. [PMID: 32486375 DOI: 10.3390/ijms21113949] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
90 Paderi A, Giorgione R, Giommoni E, Mela MM, Rossi V, Doni L, Minervini A, Carini M, Pillozzi S, Antonuzzo L. Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:860. [PMID: 33670634 DOI: 10.3390/cancers13040860] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
91 Nguyen T, Avci NG, Shin DH, Martinez-Velez N, Jiang H. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses. Cancers (Basel) 2018;10:E171. [PMID: 29857493 DOI: 10.3390/cancers10060171] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
92 Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35-45. [PMID: 12509765 DOI: 10.1038/nrc971] [Cited by in Crossref: 334] [Cited by in F6Publishing: 311] [Article Influence: 17.6] [Reference Citation Analysis]
93 Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev 2020;84:101977. [PMID: 32018128 DOI: 10.1016/j.ctrv.2020.101977] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
94 Stasikowska-Kanicka O, Wągrowska-Danilewicz M, Danilewicz M. CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. APMIS 2018;126:732-8. [PMID: 30160018 DOI: 10.1111/apm.12881] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
95 Gaponova AV, Rodin S, Mazina AA, Volchkov PV. Epithelial-Mesenchymal Transition: Role in Cancer Progression and the Perspectives of Antitumor Treatment. Acta Naturae 2020;12:4-23. [PMID: 33173593 DOI: 10.32607/actanaturae.11010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treat Rev 2018;66:104-13. [PMID: 29730461 DOI: 10.1016/j.ctrv.2018.04.004] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
97 Chaput N, Conforti R, Viaud S, Spatz A, Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene 2008;27:5920-31. [PMID: 18836473 DOI: 10.1038/onc.2008.270] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.6] [Reference Citation Analysis]
98 Chang W, Kim J, Kim Y, Kim Y, Lee J, Azuma M, Yagita H, Kang C. Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy. J Immunol 2008;181:6707-10. [DOI: 10.4049/jimmunol.181.10.6707] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 7.6] [Reference Citation Analysis]
99 Pinto Marques H, Gomes da Silva S, De Martin E, Agopian VG, Martins PN. Emerging biomarkers in HCC patients: Current status. Int J Surg 2020;82S:70-6. [PMID: 32344023 DOI: 10.1016/j.ijsu.2020.04.043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
100 Zhang F, Qi X, Wang X, Wei D, Wu J, Feng L, Cai H, Wang Y, Zeng N, Xu T, Zhou A, Zheng Y. Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget 2017;8:90215-24. [PMID: 29163822 DOI: 10.18632/oncotarget.21652] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
101 Alessandrino F, Gujrathi R, Nassar AH, Alzaghal A, Ravi A, McGregor B, Sonpavde G, Shinagare AB. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. Eur Urol Oncol 2020;3:680-6. [PMID: 31412003 DOI: 10.1016/j.euo.2019.02.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
102 Nakao S, Arai Y, Tasaki M, Yamashita M, Murakami R, Kawase T, Amino N, Nakatake M, Kurosaki H, Mori M, Takeuchi M, Nakamura T. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Sci Transl Med 2020;12:eaax7992. [PMID: 31941828 DOI: 10.1126/scitranslmed.aax7992] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 39.0] [Reference Citation Analysis]
103 Deng R, Cassady K, Li X, Yao S, Zhang M, Racine J, Lin J, Chen L, Zeng D. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease. J Immunol 2015;194:560-74. [PMID: 25488990 DOI: 10.4049/jimmunol.1402157] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
104 Rangachari D, Brahmer JR. Targeting the Immune System in the Treatment of Non-Small-Cell Lung Cancer. Curr Treat Options in Oncol 2013;14:580-94. [DOI: 10.1007/s11864-013-0250-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
105 Kwiecień I, Rutkowska E, Polubiec-Kownacka M, Raniszewska A, Rzepecki P, Domagała-Kulawik J. Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry. Transl Lung Cancer Res 2021;10:1679-89. [PMID: 34012784 DOI: 10.21037/tlcr-20-1103] [Reference Citation Analysis]
106 Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014;9:1036-40. [PMID: 24926549 DOI: 10.1097/JTO.0000000000000177] [Cited by in Crossref: 150] [Cited by in F6Publishing: 70] [Article Influence: 21.4] [Reference Citation Analysis]
107 Liu S, Han Z, Trivett AL, Lin H, Hannifin S, Yang, Oppenheim JJ. Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma. Cancer Immunol Immunother 2019;68:1059-71. [PMID: 30972427 DOI: 10.1007/s00262-019-02326-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
108 Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res. 2015;3:399-411. [PMID: 25678581 DOI: 10.1158/2326-6066.cir-14-0215] [Cited by in Crossref: 242] [Cited by in F6Publishing: 171] [Article Influence: 34.6] [Reference Citation Analysis]
109 Lin S, Huang G, Cheng L, Li Z, Xiao Y, Deng Q, Jiang Y, Li B, Lin S, Wang S, Wu Q, Yao H, Cao S, Li Y, Liu P, Wei W, Pei D, Yao Y, Wen Z, Zhang X, Wu Y, Zhang Z, Cui S, Sun X, Qian X, Li P. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs 2018;10:1301-11. [PMID: 30204048 DOI: 10.1080/19420862.2018.1518948] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
110 Oh T, Ivan ME, Sun MZ, Safaee M, Fakurnejad S, Clark AJ, Sayegh ET, Bloch O, Parsa AT. PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. Immunotherapy 2014;6:737-53. [PMID: 25186604 DOI: 10.2217/imt.14.35] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
111 Hondelink LM, Hüyük M, Postmus PE, Smit VTHBM, Blom S, von der Thüsen JH, Cohen D. Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer. Histopathology 2021. [PMID: 34786761 DOI: 10.1111/his.14571] [Reference Citation Analysis]
112 Elsayad K, Stadler R, Steinbrink K, Eich HT. Combined total skin radiotherapy and immune checkpoint inhibitors: A promising potential treatment for mycosis fungoides and Sezary syndrome. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2020;18:193-7. [DOI: 10.1111/ddg.14044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Yasuoka H, Asai A, Ohama H, Tsuchimoto Y, Fukunishi S, Higuchi K. Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis. Sci Rep 2020;10:10377. [PMID: 32587357 DOI: 10.1038/s41598-020-67497-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
114 Leufven E, Bruserud Ø. Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments. Curr Med Chem 2019;26:5244-61. [PMID: 30907305 DOI: 10.2174/0929867326666190325095853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
115 Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 2006;25:6800-6816. [PMID: 17072329 DOI: 10.1038/sj.onc.1209938] [Cited by in Crossref: 299] [Cited by in F6Publishing: 288] [Article Influence: 18.7] [Reference Citation Analysis]
116 Leng X, Wei S, Mei J, Deng S, Yang Z, Liu Z, Guo C, Deng Y, Xia L, Cheng J, Zhao K, Gan F, Li C, Merrell KW, Molina JR, Metro G, Liu L. Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma. Transl Lung Cancer Res 2021;10:965-80. [PMID: 33718036 DOI: 10.21037/tlcr-21-146] [Reference Citation Analysis]
117 Dovedi SJ, Illidge TM. The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. Oncoimmunology 2015;4:e1016709. [PMID: 26140246 DOI: 10.1080/2162402X.2015.1016709] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 6.9] [Reference Citation Analysis]
118 Qi ZJ, Yu D, Chen CH, Jiang H, Li R, Kang YM. The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis. Int J Biol Markers 2019;34:373-80. [PMID: 31608800 DOI: 10.1177/1724600819881147] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
119 Shakerin P, Sedighi Moghadam B, Baghaei K, Safaei Naraghi Z, Kamyab Hesari K, Asadzadeh Aghdaei H, Shokouhi Shoormasti R, Fazeli MS, Nourizadeh M. Increasing the expression of programmed death ligand 2 (PD-L2) but not 4-1BB ligand in colorectal cancer cells. Mol Biol Rep 2020;47:5689-97. [PMID: 32661872 DOI: 10.1007/s11033-020-05289-7] [Reference Citation Analysis]
120 Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, Kluger HM, Jilaveanu LB. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015;6:24990-5002. [PMID: 26317902 DOI: 10.18632/oncotarget.4572] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
121 Zeng Y, Li B, Liang Y, Reeves PM, Qu X, Ran C, Liu Q, Callahan MV, Sluder AE, Gelfand JA, Chen H, Poznansky MC. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J 2019;33:6596-608. [PMID: 30802149 DOI: 10.1096/fj.201802067RR] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 16.7] [Reference Citation Analysis]
122 Racz JM, Block MS, Baum CL, Jakub JW. Management of local or regional non‐nodal disease. J Surg Oncol 2018;119:187-99. [DOI: 10.1002/jso.25330] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
123 Seifert L, Miller G. Molecular Pathways: The Necrosome-A Target for Cancer Therapy. Clin Cancer Res 2017;23:1132-6. [PMID: 27932417 DOI: 10.1158/1078-0432.CCR-16-0968] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
124 Palena C, Schlom J. Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol 2010;2010:380697. [PMID: 20300434 DOI: 10.1155/2010/380697] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
125 Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother 2016;12:2777-89. [PMID: 27398650 DOI: 10.1080/21645515.2016.1199310] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
126 Mouratidis PXE, Costa M, Rivens I, Repasky EE, Ter Haar G. Pulsed focused ultrasound can improve the anti-cancer effects of immune checkpoint inhibitors in murine pancreatic cancer. J R Soc Interface 2021;18:20210266. [PMID: 34229458 DOI: 10.1098/rsif.2021.0266] [Reference Citation Analysis]
127 Ishikawa E, Satou A, Nakamura M, Nakamura S, Fujishiro M. Epstein-Barr Virus Positive B-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract. Cancers (Basel) 2021;13:3815. [PMID: 34359715 DOI: 10.3390/cancers13153815] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
128 Ha H, Nam AR, Bang JH, Park JE, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ, Oh DY. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget 2016;7:76604-12. [PMID: 27780932 DOI: 10.18632/oncotarget.12810] [Cited by in Crossref: 51] [Cited by in F6Publishing: 59] [Article Influence: 12.8] [Reference Citation Analysis]
129 Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002;3:999-1005. [PMID: 12407407 DOI: 10.1038/ni1102-999] [Cited by in Crossref: 706] [Cited by in F6Publishing: 604] [Article Influence: 35.3] [Reference Citation Analysis]
130 Lv D, Xing C, Cao L, Zhuo Y, Wu T, Gao N. PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer. Oncol Lett 2020;19:1223-34. [PMID: 31966052 DOI: 10.3892/ol.2019.11221] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
131 Umakoshi K, Choudhury ME, Nishioka R, Matsumoto H, Abe N, Nishikawa Y, Kikuchi S, Takeba J, Yano H, Yorozuya T, Sato N, Aibiki M, Tanaka J. B lymphocytopenia and Bregs in a not-to-die murine sepsis model. Biochem Biophys Res Commun 2020;523:202-7. [PMID: 31843193 DOI: 10.1016/j.bbrc.2019.12.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
132 Tietze JK, Angelova D, Heppt MV, Reinholz M, Murphy WJ, Spannagl M, Ruzicka T, Berking C. The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. Eur J Cancer 2017;75:268-79. [PMID: 28242504 DOI: 10.1016/j.ejca.2016.12.031] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
133 Bidnur S, Savdie R, Black PC. Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer 2016;2:15-25. [PMID: 27376121 DOI: 10.3233/BLC-150026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
134 Wilkins JJ, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S, Bello CL, Neuteboom B, Wade JR, Girard P, Khandelwal A. Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma. CPT Pharmacometrics Syst Pharmacol 2019;8:415-27. [PMID: 30980481 DOI: 10.1002/psp4.12406] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
135 Zhou X, Li Y, Ji Y, Liu T, Zhao N, He J, Yao J. PD-1 Involvement in Peripheral Blood CD8+ T Lymphocyte Dysfunction in Patients with Acute-on-chronic Liver Failure. J Clin Transl Hepatol 2021;9:283-90. [PMID: 34221914 DOI: 10.14218/JCTH.2020.00142] [Reference Citation Analysis]
136 Zhang H, Watanabe R, Berry GJ, Vaglio A, Liao YJ, Warrington KJ, Goronzy JJ, Weyand CM. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A 2017;114:E970-9. [PMID: 28115719 DOI: 10.1073/pnas.1616848114] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 20.8] [Reference Citation Analysis]
137 Wang J, Zhang L, Kang D, Yang D, Tang Y. Activation of PGE2/EP2 and PGE2/EP4 signaling pathways positively regulate the level of PD-1 in infiltrating CD8+ T cells in patients with lung cancer. Oncol Lett 2018;15:552-8. [PMID: 29285200 DOI: 10.3892/ol.2017.7279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
138 Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 2013;19:3165-75. [PMID: 23613317 DOI: 10.1158/1078-0432.CCR-12-3314] [Cited by in Crossref: 242] [Cited by in F6Publishing: 181] [Article Influence: 26.9] [Reference Citation Analysis]
139 Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J Immunol 2011;186:6822-9. [PMID: 21555531 DOI: 10.4049/jimmunol.1003682] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
140 Gilboa E. The promise of cancer vaccines. Nat Rev Cancer. 2004;4:401-411. [PMID: 15122211 DOI: 10.1038/nrc1359] [Cited by in Crossref: 193] [Cited by in F6Publishing: 161] [Article Influence: 10.7] [Reference Citation Analysis]
141 Bates AM, Lanzel EA, Qian F, Abbasi T, Vali S, Brogden KA. Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study. Oral Surg Oral Med Oral Pathol Oral Radiol 2017;124:157-64. [PMID: 28756882 DOI: 10.1016/j.oooo.2017.05.474] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
142 Domblides C, Antoine M, Hamard C, Rabbe N, Rodenas A, Vieira T, Crequit P, Cadranel J, Lavolé A, Wislez M. Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates. AIDS 2018;32:461-8. [PMID: 29194117 DOI: 10.1097/QAD.0000000000001713] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
143 Meng X, Gao Y, Yang L, Jing H, Teng F, Huang Z, Xing L. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis. Clin Lung Cancer 2019;20:48-58. [PMID: 30341017 DOI: 10.1016/j.cllc.2018.09.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
144 Sumimoto H, Takano A, Teramoto K, Daigo Y. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers. PLoS One 2016;11:e0166626. [PMID: 27846317 DOI: 10.1371/journal.pone.0166626] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 13.3] [Reference Citation Analysis]
145 Shen L, Zhou T, Fan Y, Chang X, Wang Y, Sun J, Xing L, Jiang H. Recent progress in tumor photodynamic immunotherapy. Chinese Chemical Letters 2020;31:1709-16. [DOI: 10.1016/j.cclet.2020.02.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
146 Qiao B, Huang J, Mei Z, Lam AK, Zhao J, Ying L. Analysis of Immune Microenvironment by Multiplex Immunohistochemistry Staining in Different Oral Diseases and Oral Squamous Cell Carcinoma. Front Oncol 2020;10:555757. [PMID: 33364188 DOI: 10.3389/fonc.2020.555757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
147 Ogunleye F, Blankenship L, Millisor V, Anderson J, Jaiyesimi I. Programmed cell death-1/Programmed cell death ligand-1(PD-1/PD-L1) inhibitors, heralding a new era of immunotherapy in the management of advanced Non-Small Cell Lung Cancer (NSCLC). Cancer Treatment and Research Communications 2017;12:6-13. [DOI: 10.1016/j.ctarc.2017.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
148 Nam J, Son S, Park KS, Zou W, Shea LD, Moon JJ. Cancer nanomedicine for combination cancer immunotherapy. Nat Rev Mater 2019;4:398-414. [DOI: 10.1038/s41578-019-0108-1] [Cited by in Crossref: 261] [Cited by in F6Publishing: 147] [Article Influence: 87.0] [Reference Citation Analysis]
149 Saito H, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol. 2013;107:517-522. [PMID: 23129549 DOI: 10.1002/jso.23281] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
150 Garrido F. MHC/HLA Class I Loss in Cancer Cells. Adv Exp Med Biol 2019;1151:15-78. [PMID: 31140106 DOI: 10.1007/978-3-030-17864-2_2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
151 Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. J Cancer 2014;5:166-72. [PMID: 24563671 DOI: 10.7150/jca.8167] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 12.8] [Reference Citation Analysis]
152 Mukaigawa T, Hayashi R, Hashimoto K, Ugumori T, Hato N, Fujii S. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J Surg Oncol 2016;114:36-43. [PMID: 27111278 DOI: 10.1002/jso.24266] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
153 Pang L, Han S, Jiao Y, Jiang S, He X, Li P. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation. Int J Oncol 2017;51:25-38. [PMID: 28534943 DOI: 10.3892/ijo.2017.4014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
154 Schneider MA, Heeb L, Beffinger MM, Pantelyushin S, Linecker M, Roth L, Lehmann K, Ungethüm U, Kobold S, Graf R, van den Broek M, Vom Berg J, Gupta A, Clavien PA. Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Sci Transl Med 2021;13:eabc8188. [PMID: 34524861 DOI: 10.1126/scitranslmed.abc8188] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Zhang J, Dang F, Ren J, Wei W. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends Biochem Sci 2018;43:1014-32. [PMID: 30287140 DOI: 10.1016/j.tibs.2018.09.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 14.0] [Reference Citation Analysis]
156 Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, Fusai G, Vargas FA, Tan ZMD, Aw JYJ, Hansi N, Kennedy PTF, Xue SA, Stauss HJ, Bertoletti A, Pavesi A, Maini MK. Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Mol Ther 2018;26:2553-66. [PMID: 30217730 DOI: 10.1016/j.ymthe.2018.08.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
157 Guo S, Xiao P, Li B, Wang W, Wang S, Lv T, Xu X, Chen C, Huang L, Li Z, Tang L, Peng L, Wang H. Co-immunizing with PD-L1 induces CD8+ DCs-mediated anti-tumor immunity in multiple myeloma. Int Immunopharmacol 2020;84:106516. [PMID: 32334387 DOI: 10.1016/j.intimp.2020.106516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Front Pharmacol 2021;12:731798. [PMID: 34539412 DOI: 10.3389/fphar.2021.731798] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Phillips T, Millett MM, Zhang X, Jansson M, Cleveland R, Simmons P, Cherryholmes G, Carnahan J, William J, Spaulding B, Satnick IR, Inzunza HD, Taylor C, Cogswell J, Novotny J, Oroudjev E, Winther H. Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma. Appl Immunohistochem Mol Morphol 2018;26:6-12. [PMID: 29189265 DOI: 10.1097/PAI.0000000000000605] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
160 Kim YJ, Park SJ, Broxmeyer HE. Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction. J Immunol 2011;187:2291-301. [PMID: 21795591 DOI: 10.4049/jimmunol.1002650] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
161 Fraser NJ, Howie J, Wypijewski KJ, Fuller W. Therapeutic targeting of protein S-acylation for the treatment of disease. Biochemical Society Transactions 2020;48:281-90. [DOI: 10.1042/bst20190707] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
162 Huang TY, Chang TC, Chin YT, Pan YS, Chang WJ, Liu FC, Hastuti ED, Chiu SJ, Wang SH, Changou CA, Li ZL, Chen YR, Chu HR, Shih YJ, Cheng RH, Wu A, Lin HY, Wang K, Whang-Peng J, Mousa SA, Davis PJ. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer. Cells 2020;9:E1830. [PMID: 32756527 DOI: 10.3390/cells9081830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
163 Binello E, Germano IM. Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci 2011;102:1958-66. [PMID: 21848914 DOI: 10.1111/j.1349-7006.2011.02064.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
164 Dimitrov V, Bouttier M, Boukhaled G, Salehi-Tabar R, Avramescu RG, Memari B, Hasaj B, Lukacs GL, Krawczyk CM, White JH. Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice. J Biol Chem 2017;292:20657-68. [PMID: 29061851 DOI: 10.1074/jbc.M117.793885] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
165 Feucht J, Kayser S, Gorodezki D, Hamieh M, Döring M, Blaeschke F, Schlegel P, Bösmüller H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 2016;7:76902-19. [PMID: 27708227 DOI: 10.18632/oncotarget.12357] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 19.8] [Reference Citation Analysis]
166 Ji S, Lee J, Lee ES, Kim DH, Sin JI. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. Hum Vaccin Immunother 2021;17:1910-22. [PMID: 33522416 DOI: 10.1080/21645515.2020.1866951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
167 Dill EA, Dillon PM, Bullock TN, Mills AM. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. Mod Pathol. 2018;31:1513-1522. [PMID: 29802358 DOI: 10.1038/s41379-018-0061-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
168 Chen Y, Hu Z, Wang Q, Ge Y, Bai L, Wang X, Zhang X. Generation and characterization of four novel monoclonal antibodies against human programmed death-1 molecule. Hybridoma (Larchmt) 2010;29:153-60. [PMID: 20443708 DOI: 10.1089/hyb.2009.0091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
169 Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, Xie Z, Yan LX, Su J, Yang JJ, Zhong WZ, Zhang XC, Wu YL. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. J Thorac Oncol 2018;13:521-32. [PMID: 29269008 DOI: 10.1016/j.jtho.2017.11.132] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 10.4] [Reference Citation Analysis]
170 Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023-5039. [PMID: 27574444 DOI: 10.2147/ott.s105862] [Cited by in Crossref: 297] [Cited by in F6Publishing: 192] [Article Influence: 49.5] [Reference Citation Analysis]
171 Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, Pavelko KD, Li Y, O'Brien D, Wang C, Graham RP, Smoot RL, Dong H, Ilyas S. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest 2020;130:5380-96. [PMID: 32663198 DOI: 10.1172/JCI137110] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 23.0] [Reference Citation Analysis]
172 Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T, Zhou A. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017;3:17004. [PMID: 28280600 DOI: 10.1038/celldisc.2017.4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 14.0] [Reference Citation Analysis]
173 Fan P, Ma J, Jin X. Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1. Biochemical and Biophysical Research Communications 2018;505:830-6. [DOI: 10.1016/j.bbrc.2018.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
174 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017;8:91779-94. [PMID: 29207684 DOI: 10.18632/oncotarget.21586] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 32.8] [Reference Citation Analysis]
175 Hobson-Gutierrez SA, Carmona-Fontaine C. The metabolic axis of macrophage and immune cell polarization. Dis Model Mech. 2018;11. [PMID: 29991530 DOI: 10.1242/dmm.034462] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
176 Wudtiwai B, Makeudom A, Krisanaprakornkit S, Pothacharoen P, Kongtawelert P. Anticancer Activities of Hesperidin via Suppression of Up-Regulated Programmed Death-Ligand 1 Expression in Oral Cancer Cells. Molecules 2021;26:5345. [PMID: 34500779 DOI: 10.3390/molecules26175345] [Reference Citation Analysis]
177 Wang JJ, Siu MK, Jiang YX, Leung TH, Chan DW, Wang HG, Ngan HY, Chan KK. A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer. Biomolecules 2021;11:1749. [PMID: 34944392 DOI: 10.3390/biom11121749] [Reference Citation Analysis]
178 Francis DM, Thomas SN. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. Adv Drug Deliv Rev 2017;114:33-42. [PMID: 28455187 DOI: 10.1016/j.addr.2017.04.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
179 Alderson KL, Murphy WJ. Antigen Specific Memory T Cells and Their Putative Need for the Generation of Sustained Anti-Tumor Responses. In: Zanetti M, Schoenberger SP, editors. Memory T Cells. New York: Springer; 2010. pp. 155-65. [DOI: 10.1007/978-1-4419-6451-9_12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
180 Groeger S, Meyle J. Oral Mucosal Epithelial Cells. Front Immunol 2019;10:208. [PMID: 30837987 DOI: 10.3389/fimmu.2019.00208] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 20.7] [Reference Citation Analysis]
181 Grzywnowicz M, Zaleska J, Mertens D, Tomczak W, Wlasiuk P, Kosior K, Piechnik A, Bojarska-Junak A, Dmoszynska A, Giannopoulos K. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One 2012;7:e35178. [PMID: 22532845 DOI: 10.1371/journal.pone.0035178] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
182 Gong TJ, Tang F, Zheng CX, Wang J, Wang YT, Zhang YH, Luo Y, Zhou Y, Min L, Tu CQ. Case Report: Pulmonary Metastases From Epithelioid Sarcoma in Extremity Favourably Responding to Immunotherapy With Camrelizumab. Front Oncol 2021;11:728437. [PMID: 34692503 DOI: 10.3389/fonc.2021.728437] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ, Sato T. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy 2017;9:1323-30. [PMID: 29185395 DOI: 10.2217/imt-2017-0066] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
184 Minassian LM, Cotechini T, Huitema E, Graham CH. Hypoxia-Induced Resistance to Chemotherapy in Cancer. Adv Exp Med Biol 2019;1136:123-39. [PMID: 31201721 DOI: 10.1007/978-3-030-12734-3_9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
185 Fontugne J, Augustin J, Pujals A, Compagnon P, Rousseau B, Luciani A, Tournigand C, Cherqui D, Azoulay D, Pawlotsky JM, Calderaro J. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 2017;8:24644-51. [PMID: 28445951 DOI: 10.18632/oncotarget.15602] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 19.5] [Reference Citation Analysis]
186 Barach YS, Lee JS, Zang X. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med 2011;17:47-55. [PMID: 20971039 DOI: 10.1016/j.molmed.2010.09.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
187 Petroff MG, Chen L, Phillips TA, Azzola D, Sedlmayr P, Hunt JS. B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol Reprod 2003;68:1496-504. [PMID: 12606489 DOI: 10.1095/biolreprod.102.010058] [Cited by in Crossref: 135] [Cited by in F6Publishing: 125] [Article Influence: 6.8] [Reference Citation Analysis]
188 Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncology 2015;11:1307-26. [DOI: 10.2217/fon.15.52] [Cited by in Crossref: 106] [Cited by in F6Publishing: 103] [Article Influence: 15.1] [Reference Citation Analysis]
189 Azim HA Jr, Brohée S, Peccatori FA, Desmedt C, Loi S, Lambrechts D, Dell'Orto P, Majjaj S, Jose V, Rotmensz N, Ignatiadis M, Pruneri G, Piccart M, Viale G, Sotiriou C. Biology of breast cancer during pregnancy using genomic profiling. Endocr Relat Cancer 2014;21:545-54. [PMID: 24825746 DOI: 10.1530/ERC-14-0111] [Cited by in Crossref: 42] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
190 Thar Min AK, Okayama H, Saito M, Ashizawa M, Aoto K, Nakajima T, Saito K, Hayase S, Sakamoto W, Tada T, Hanayama H, Saze Z, Momma T, Ohki S, Sato Y, Motoyama S, Mimura K, Kono K. Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma. Cancer Med 2018. [PMID: 29855157 DOI: 10.1002/cam4.1564] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
191 Xiong W, Gao Y, Wei W, Zhang J. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends Cancer 2021;7:837-46. [PMID: 33903073 DOI: 10.1016/j.trecan.2021.03.003] [Reference Citation Analysis]
192 Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 2018;128:805-15. [PMID: 29337305 DOI: 10.1172/JCI96113] [Cited by in Crossref: 207] [Cited by in F6Publishing: 147] [Article Influence: 51.8] [Reference Citation Analysis]
193 Li J, Dong C. Nobel goes to immune checkpoint-Innovative cancer treatment by immunotherapy. Sci China Life Sci 2018;61:1445-50. [PMID: 30377902 DOI: 10.1007/s11427-018-9409-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
194 Gong N, Zhang Y, Zhang Z, Li X, Liang X. Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. Adv Funct Mater 2019;29:1806087. [DOI: 10.1002/adfm.201806087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
195 Kamphorst AO, Araki K, Ahmed R. Beyond adjuvants: immunomodulation strategies to enhance T cell immunity. Vaccine 2015;33 Suppl 2:B21-8. [PMID: 26022562 DOI: 10.1016/j.vaccine.2014.12.082] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
196 Wolfson B, Franks SE, Hodge JW. Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. Vaccines (Basel) 2021;9:509. [PMID: 34063388 DOI: 10.3390/vaccines9050509] [Reference Citation Analysis]
197 Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016;17:1374-85. [PMID: 27592805 DOI: 10.1016/S1470-2045(16)30364-3] [Cited by in Crossref: 717] [Cited by in F6Publishing: 376] [Article Influence: 119.5] [Reference Citation Analysis]
198 Singh S, Numan A, Agrawal N, Tambuwala MM, Singh V, Kesharwani P. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care. Int Immunopharmacol 2020;83:106417. [PMID: 32200155 DOI: 10.1016/j.intimp.2020.106417] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
199 Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 2016;12:2219-31. [PMID: 27135835 DOI: 10.1080/21645515.2016.1175694] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
200 Palma M, Gentilcore G, Heimersson K, Mozaffari F, Näsman-Glaser B, Young E, Rosenquist R, Hansson L, Österborg A, Mellstedt H. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica 2017;102:562-72. [PMID: 27927767 DOI: 10.3324/haematol.2016.151100] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 11.5] [Reference Citation Analysis]
201 Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caracò C, Botti G, Fox BA, Ascierto PA. PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. Oncoimmunology 2018;7:e1405206. [PMID: 30524879 DOI: 10.1080/2162402X.2017.1405206] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
202 Berezhnoy A, Sumrow BJ, Stahl K, Shah K, Liu D, Li J, Hao SS, De Costa A, Kaul S, Bendell J, Cote GM, Luke JJ, Sanborn RE, Sharma MR, Chen F, Li H, Diedrich G, Bonvini E, Moore PA. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med 2020;1:100163. [PMID: 33377134 DOI: 10.1016/j.xcrm.2020.100163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
203 Goyne HE, Cannon MJ. Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer. Front Immunol 2013;4:382. [PMID: 24302925 DOI: 10.3389/fimmu.2013.00382] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
204 Grotz TE, Mansfield AS, Jakub JW, Markovic SN. Regional lymphatic immunity in melanoma. Melanoma Res 2012;22:9-18. [PMID: 22082957 DOI: 10.1097/CMR.0b013e32834e1f33] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
205 Modena A, Ciccarese C, Iacovelli R, Brunelli M, Montironi R, Fiorentino M, Tortora G, Massari F. Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev 2016;10:293. [PMID: 27471580 DOI: 10.4081/oncol.2016.293] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
206 Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun 2017;8:14754. [PMID: 28345650 DOI: 10.1038/ncomms14754] [Cited by in Crossref: 136] [Cited by in F6Publishing: 144] [Article Influence: 27.2] [Reference Citation Analysis]
207 Pulko V, Harris KJ, Liu X, Gibbons RM, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-h1 expressed by activated CD8 T cells is essential for their survival. J Immunol. 2011;187:5606-5614. [PMID: 22025548 DOI: 10.4049/jimmunol.1003976] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
208 Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27:1492-1504. [PMID: 27207108 DOI: 10.1093/annonc/mdw217] [Cited by in Crossref: 219] [Cited by in F6Publishing: 211] [Article Influence: 36.5] [Reference Citation Analysis]
209 Gedye C, Hogg D, Butler M, Joshua AM. New treatments for metastatic melanoma. CMAJ 2014;186:754-60. [PMID: 24549129 DOI: 10.1503/cmaj.130989] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
210 Jurado JO, Alvarez IB, Pasquinelli V, Martínez GJ, Quiroga MF, Abbate E, Musella RM, Chuluyan HE, García VE. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 2008;181:116-25. [PMID: 18566376 DOI: 10.4049/jimmunol.181.1.116] [Cited by in Crossref: 176] [Cited by in F6Publishing: 170] [Article Influence: 12.6] [Reference Citation Analysis]
211 Chen YF, Wang YH, Lei CS, Changou CA, Davis ME, Yen Y. Host immune response to anti-cancer camptothecin conjugated cyclodextrin-based polymers. J Biomed Sci 2019;26:85. [PMID: 31647037 DOI: 10.1186/s12929-019-0583-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
212 Pu X, Wu L, Su D, Mao W, Fang B. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer 2018;18:1082. [PMID: 30409126 DOI: 10.1186/s12885-018-4990-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
213 Wang Y, Goliwas KF, Severino PE, Hough KP, Van Vessem D, Wang H, Tousif S, Koomullil RP, Frost AR, Ponnazhagan S, Berry JL, Deshane JS. Mechanical strain induces phenotypic changes in breast cancer cells and promotes immunosuppression in the tumor microenvironment. Lab Invest 2020;100:1503-16. [PMID: 32572176 DOI: 10.1038/s41374-020-0452-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
214 Leite KR, Reis ST, Junior JP, Zerati M, Gomes Dde O, Camara-Lopes LH, Srougi M. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn Pathol 2015;10:189. [PMID: 26470780 DOI: 10.1186/s13000-015-0414-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 6.7] [Reference Citation Analysis]
215 Vathiotis IA, Gomatou G, Stravopodis DJ, Syrigos N. Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis. Int J Mol Sci 2021;22:5383. [PMID: 34065396 DOI: 10.3390/ijms22105383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018;8:216-233. [PMID: 29101163 DOI: 10.1158/2159-8290.cd-17-0915] [Cited by in Crossref: 217] [Cited by in F6Publishing: 134] [Article Influence: 43.4] [Reference Citation Analysis]
217 Tang PA, Heng DY. Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep 2013;15:98-104. [PMID: 23263823 DOI: 10.1007/s11912-012-0284-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
218 Wilke CM, Wei S, Wang L, Kryczek I, Kao J, Zou W. Dual biological effects of the cytokines interleukin-10 and interferon-γ. Cancer Immunol Immunother. 2011;60:1529-1541. [PMID: 21918895 DOI: 10.1007/s00262-011-1104-5] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 8.1] [Reference Citation Analysis]
219 Khunger A, Battel L, Wadhawan A, More A, Kapoor A, Agrawal N. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. Curr Oncol Rep 2020;22. [DOI: 10.1007/s11912-020-00925-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
220 Byers J, Yin H, Rytting H, Logan S, He M, Yu Z, Wang D, Warren M, Mangray S, Dehner LP, Zhou S. PD-L1 expression in angiomatoid fibrous histiocytoma. Sci Rep 2021;11:2183. [PMID: 33500467 DOI: 10.1038/s41598-021-81746-y] [Reference Citation Analysis]
221 Wang M, Ma X, Guo L, Xia F. Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug Des Devel Ther 2017;11:2851-60. [PMID: 29033546 DOI: 10.2147/DDDT.S146286] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
222 Qu S, Jiao Z, Lu G, Yao B, Wang T, Rong W, Xu J, Fan T, Sun X, Yang R, Wang J, Yao Y, Xu G, Yan X, Wang T, Liang H, Zen K. PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biol 2021;22:104. [PMID: 33849634 DOI: 10.1186/s13059-021-02331-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol. 2017;50:41-48. [PMID: 27922697 DOI: 10.3892/ijo.2016.3785] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
224 Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai M, Hellstrom I, Hellstrom KE, Guo Y. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 2013;8:e84927. [PMID: 24367702 DOI: 10.1371/journal.pone.0084927] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
225 Zhang L, Zhang X, Liu Y, Zhang T, Wang Z, Gu M, Li Y, Wang DD, Li W, Lin PP. PD-L1+ aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients. Cancer Letters 2020;469:355-66. [DOI: 10.1016/j.canlet.2019.10.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
226 AiErken N, Shi HJ, Zhou Y, Shao N, Zhang J, Shi Y, Yuan ZY, Lin Y. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. Int J Biol Sci 2017;13:1172-9. [PMID: 29104508 DOI: 10.7150/ijbs.20868] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
227 Shao L, Peng Q, Du K, He J, Dong Y, Lin X, Li J, Wu J. Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy. Cancer Manag Res 2017;9:249-58. [PMID: 28721097 DOI: 10.2147/CMAR.S139889] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
228 Mizugaki H, Yamamoto N, Murakami H, Kenmotsu H, Fujiwara Y, Ishida Y, Kawakami T, Takahashi T. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Invest New Drugs 2016;34:596-603. [PMID: 27363843 DOI: 10.1007/s10637-016-0371-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
229 Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR, Castro MG. Overview of current immunotherapeutic strategies for glioma. Immunotherapy 2015;7:1073-104. [PMID: 26598957 DOI: 10.2217/imt.15.75] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
230 Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008;14:550-9. [PMID: 18986838 DOI: 10.1016/j.molmed.2008.09.010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
231 Wang B, Sun L, Yuan Z, Tao Z. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation. Med Oncol 2020;37:66. [PMID: 32696094 DOI: 10.1007/s12032-020-01390-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
232 Bongiorno EK, Garcia SA, Sauma S, Hooper DC. Type 1 Immune Mechanisms Driven by the Response to Infection with Attenuated Rabies Virus Result in Changes in the Immune Bias of the Tumor Microenvironment and Necrosis of Mouse GL261 Brain Tumors. J Immunol 2017;198:4513-23. [PMID: 28461570 DOI: 10.4049/jimmunol.1601444] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
233 Zikich D, Schachter J, Besser MJ. Immunotherapy for the management of advanced melanoma: the next steps. Am J Clin Dermatol 2013;14:261-72. [PMID: 23516145 DOI: 10.1007/s40257-013-0013-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
234 Chang ZL, Silver PA, Chen YY. Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors. J Transl Med 2015;13:161. [PMID: 25990251 DOI: 10.1186/s12967-015-0519-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
235 Kawamura A, Kawamura T, Riddell M, Hikita T, Yanagi T, Umemura H, Nakayama M. Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma. Cancer Sci 2019;110:1780-9. [PMID: 30801864 DOI: 10.1111/cas.13981] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
236 Renuka, Agnihotri N, Bhatnagar A. Differential ratios of fish/corn oil ameliorated the colon carcinoma in rat by altering intestinal intraepithelial CD8+ T lymphocytes, dendritic cells population and modulating the intracellular cytokines. Biomedicine & Pharmacotherapy 2018;98:600-8. [DOI: 10.1016/j.biopha.2017.12.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
237 Hoesli RC, Moyer JS. Immunotherapy for Head and Neck Squamous Cell Carcinoma. Curr Oral Health Rep 2016;3:74-81. [PMID: 27398287 DOI: 10.1007/s40496-016-0082-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
238 Gomez Hernandez MP, Bates AM, Starman EE, Lanzel EA, Comnick C, Xie XJ, Brogden KA. HBD3 Induces PD-L1 Expression on Head and Neck Squamous Cell Carcinoma Cell Lines. Antibiotics (Basel) 2019;8:E161. [PMID: 31554151 DOI: 10.3390/antibiotics8040161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
239 Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ 2020;27:3209-25. [PMID: 33037393 DOI: 10.1038/s41418-020-00633-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 21.5] [Reference Citation Analysis]
240 Compérat E, Amin MB, Epstein JI, Hansel DE, Paner G, Al-Ahmadie H, True L, Bayder D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo C, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, McKenney J, Netto GJ, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupret M, Shah RB, Shariat SF, Trpkov K, Weyerer V, Zhou M, Reuter V. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Adv Anat Pathol 2021;28:196-208. [PMID: 34128484 DOI: 10.1097/PAP.0000000000000309] [Reference Citation Analysis]
241 Keam B, Ock CY, Kim TM, Oh DY, Kang WK, Park YH, Lee J, Lee JH, Ahn YH, Kim HJ, Chang SK, Park J, Choi JY, Song YJ, Park YS. A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. Invest New Drugs 2021. [PMID: 34268711 DOI: 10.1007/s10637-021-01078-6] [Reference Citation Analysis]
242 Young S, Griego-Fullbright C, Wagner A, Chargin A, Patterson BK, Chabot-Richards D. Concordance of PD-L1 Expression Detection in Non-Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC). Am J Clin Pathol 2018;150:346-52. [PMID: 30052717 DOI: 10.1093/ajcp/aqy063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
243 Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clin Cancer Res 2015;21:3052-60. [PMID: 25788491 DOI: 10.1158/1078-0432.CCR-14-3073] [Cited by in Crossref: 134] [Cited by in F6Publishing: 85] [Article Influence: 19.1] [Reference Citation Analysis]
244 Cesco-Gaspere M, Morris E, Stauss HJ. Immunomodulation in the treatment of haematological malignancies. Clin Exp Med 2009;9:81-92. [PMID: 19238515 DOI: 10.1007/s10238-009-0037-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
245 Liu YX, Wang XS, Wang YF, Hu XC, Yan JQ, Zhang YL, Wang W, Yang RJ, Feng YY, Gao SG. Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis. Onco Targets Ther. 2016;9:2649-2654. [PMID: 27226727 DOI: 10.2147/ott.s102616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.5] [Reference Citation Analysis]
246 Lengagne R, Graff-Dubois S, Garcette M, Renia L, Kato M, Guillet JG, Engelhard VH, Avril MF, Abastado JP, Prévost-Blondel A. Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J Immunol 2008;180:130-7. [PMID: 18097012 DOI: 10.4049/jimmunol.180.1.130] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
247 Rawangkan A, Wongsirisin P, Namiki K, Iida K, Kobayashi Y, Shimizu Y, Fujiki H, Suganuma M. Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth. Molecules 2018;23:E2071. [PMID: 30126206 DOI: 10.3390/molecules23082071] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
248 Prodeus A, Abdul-Wahid A, Fischer NW, Huang EH, Cydzik M, Gariépy J. Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. Mol Ther Nucleic Acids 2015;4:e237. [PMID: 25919090 DOI: 10.1038/mtna.2015.11] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 9.7] [Reference Citation Analysis]
249 Guerrero AD, Moyes JS, Cooper LJ. The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer 2014;33:421-33. [PMID: 25189715 DOI: 10.5732/cjc.014.10100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
250 Daver N, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, Kantarjian H. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 2018;32:1094-105. [PMID: 29487386 DOI: 10.1038/s41375-018-0070-8] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 22.5] [Reference Citation Analysis]
251 Kopalli SR, Kang T, Lee K, Koppula S. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. PRA 2019;14:100-12. [DOI: 10.2174/1574892813666181029142812] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
252 Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 2012;209:201-9. [PMID: 22330682 DOI: 10.1084/jem.20112275] [Cited by in Crossref: 93] [Cited by in F6Publishing: 94] [Article Influence: 9.3] [Reference Citation Analysis]
253 Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, Yamazaki T, Azuma M, Iwai H, Khoury SJ, Auchincloss H Jr, Sayegh MH. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003;198:63-9. [PMID: 12847137 DOI: 10.1084/jem.20022125] [Cited by in Crossref: 517] [Cited by in F6Publishing: 509] [Article Influence: 27.2] [Reference Citation Analysis]
254 Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57. [PMID: 18294387 DOI: 10.1186/1471-2407-8-57] [Cited by in Crossref: 143] [Cited by in F6Publishing: 138] [Article Influence: 10.2] [Reference Citation Analysis]
255 Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009;182:5240-9. [PMID: 19380770 DOI: 10.4049/jimmunol.0803245] [Cited by in Crossref: 126] [Cited by in F6Publishing: 113] [Article Influence: 9.7] [Reference Citation Analysis]
256 Liu X, Gao JX, Wen J, Yin L, Li O, Zuo T, Gajewski TF, Fu YX, Zheng P, Liu Y. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med. 2003;197:1721-1730. [PMID: 12810690 DOI: 10.1084/jem.20022089] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 5.4] [Reference Citation Analysis]
257 Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J 2014;20:256-61. [PMID: 25098285 DOI: 10.1097/PPO.0000000000000061] [Cited by in Crossref: 78] [Cited by in F6Publishing: 50] [Article Influence: 11.1] [Reference Citation Analysis]
258 DiDomenico J, Lamano JB, Oyon D, Li Y, Veliceasa D, Kaur G, Ampie L, Choy W, Lamano JB, Bloch O. The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. Oncoimmunology 2018;7:e1448329. [PMID: 29900065 DOI: 10.1080/2162402X.2018.1448329] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 9.8] [Reference Citation Analysis]
259 Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol. 2018;6:69-78. [PMID: 29607307 DOI: 10.14218/jcth.2017.00031] [Cited by in Crossref: 97] [Cited by in F6Publishing: 76] [Article Influence: 19.4] [Reference Citation Analysis]
260 Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, Murillo F, Rowley J, Tsai YC, He L, Kim DJ, Jaffee E, Pardoll D, Wu TC. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007;67:1832-41. [PMID: 17308126 DOI: 10.1158/0008-5472.CAN-06-3014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
261 Chin YT, Wei PL, Ho Y, Nana AW, Changou CA, Chen YR, Yang YS, Hsieh MT, Hercbergs A, Davis PJ, Shih YJ, Lin HY. Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells. Endocr Relat Cancer 2018;25:533-45. [PMID: 29555649 DOI: 10.1530/ERC-17-0376] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
262 Cheah CY, Fowler NH, Neelapu SS. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol 2015;27:384-91. [PMID: 26248256 DOI: 10.1097/CCO.0000000000000212] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
263 Mi Y, Han J, Zhu J, Jin T. Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions. Mol Neurobiol 2021. [PMID: 34480337 DOI: 10.1007/s12035-021-02495-7] [Reference Citation Analysis]
264 Koopmans I, Hendriks D, Samplonius DF, van Ginkel RJ, Heskamp S, Wierstra PJ, Bremer E, Helfrich W. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. Oncoimmunology 2018;7:e1466016. [PMID: 30221065 DOI: 10.1080/2162402X.2018.1466016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
265 Meng X, Liu X, Guo X, Jiang S, Chen T, Hu Z, Liu H, Bai Y, Xue M, Hu R, Sun SC, Liu X, Zhou P, Huang X, Wei L, Yang W, Xu C. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature 2018;564:130-5. [PMID: 30487606 DOI: 10.1038/s41586-018-0756-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 17.5] [Reference Citation Analysis]
266 Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, Jakopović M, Brčić L, Knežević J. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. J Pers Med 2021;11:1102. [PMID: 34834454 DOI: 10.3390/jpm11111102] [Reference Citation Analysis]
267 Wang Y, Zhuang Q, Zhou S, Hu Z, Lan R. Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance. J Huazhong Univ Sci Technolog Med Sci 2009;29:77-9. [PMID: 19224168 DOI: 10.1007/s11596-009-0116-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
268 Albertini MR, Ranheim EA, Zuleger CL, Sondel PM, Hank JA, Bridges A, Newton MA, McFarland T, Collins J, Clements E, Henry MB, Neuman HB, Weber S, Whalen G, Galili U. Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma. Cancer Immunol Immunother 2016;65:897-907. [PMID: 27207605 DOI: 10.1007/s00262-016-1846-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
269 Shashidharamurthy R, Bozeman EN, Patel J, Kaur R, Meganathan J, Selvaraj P. Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development: CANCER VACCINE DEVELOPMENT. Med Res Rev 2012;32:1197-219. [DOI: 10.1002/med.20237] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
270 Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015;15:45-56. [PMID: 25534622 DOI: 10.1038/nri3790] [Cited by in Crossref: 339] [Cited by in F6Publishing: 320] [Article Influence: 48.4] [Reference Citation Analysis]
271 Schlereth SL, Refaian N, Iden S, Cursiefen C, Heindl LM. Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. Biomed Res Int. 2014;2014:639058. [PMID: 25254213 DOI: 10.1155/2014/639058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
272 Tajiri K, Aonuma K, Sekine I. Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol 2018;48:7-12. [PMID: 29045749 DOI: 10.1093/jjco/hyx154] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
273 Zhang L, Wu L, Chen Q, Zhang B, Liu J, Liu S, Mo X, Li M, Chen Z, Chen L, You J, Jin Z, Chen X, Zhou Z, Zhang S. Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy. EClinicalMedicine 2021;31:100673. [PMID: 33554079 DOI: 10.1016/j.eclinm.2020.100673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
274 Zhang Y, Wu L, Li Z, Zhang W, Luo F, Chu Y, Chen G. Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages. Biomacromolecules 2018;19:2098-108. [DOI: 10.1021/acs.biomac.8b00305] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
275 Ock CY, Kim S, Keam B, Kim S, Ahn YO, Chung EJ, Kim JH, Kim TM, Kwon SK, Jeon YK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS. Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. Oncotarget 2017;8:97920-7. [PMID: 29228662 DOI: 10.18632/oncotarget.18542] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
276 Lee SH, Danishmalik SN, Sin JI. DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother 2015;11:1889-900. [PMID: 25984993 DOI: 10.1080/21645515.2015.1035502] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
277 Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:97-106. [PMID: 25755682 DOI: 10.1177/1758834014567469] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 13.4] [Reference Citation Analysis]
278 Hou PP, Chen HZ. Extracellular vesicles in the tumor immune microenvironment. Cancer Lett 2021;516:48-56. [PMID: 34082025 DOI: 10.1016/j.canlet.2021.05.032] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
279 Qiao J, Liu Z, Dong C, Luan Y, Zhang A, Moore C, Fu K, Peng J, Wang Y, Ren Z, Han C, Xu T, Fu YX. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis. Cancer Cell 2019;35:901-915.e4. [PMID: 31185213 DOI: 10.1016/j.ccell.2019.05.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 16.0] [Reference Citation Analysis]
280 Herbel C, Patsoukis N, Bardhan K, Seth P, Weaver JD, Boussiotis VA. Clinical significance of T cell metabolic reprogramming in cancer. Clin Transl Med 2016;5:29. [PMID: 27510264 DOI: 10.1186/s40169-016-0110-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
281 Mishra DK, Rocha HJ, Miller R, Kim MP. Immune cells inhibit the tumor metastasis in the 4D cellular lung model by reducing the number of live circulating tumor cells. Sci Rep 2018;8:16569. [PMID: 30410108 DOI: 10.1038/s41598-018-34983-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
282 Cao Y, Cao T, Zhao W, He F, Lu Y, Zhang G, Hu H, Wang Z. Expression of B7-H2 on CD8+ T cells in colorectal cancer microenvironment and its clinical significance. Int Immunopharmacol 2018;56:128-34. [PMID: 29414642 DOI: 10.1016/j.intimp.2018.01.018] [Reference Citation Analysis]
283 Ghosh S, Nataraj NB, Noronha A, Patkar S, Sekar A, Mukherjee S, Winograd-Katz S, Kramarski L, Verma A, Lindzen M, Garcia DD, Green J, Eisenberg G, Gil-Henn H, Basu A, Lender Y, Weiss S, Oren M, Lotem M, Geiger B, Ruppin E, Yarden Y. PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. Cell Rep 2021;35:109181. [PMID: 34038737 DOI: 10.1016/j.celrep.2021.109181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
284 Zoroquiain P, Esposito E, Logan P, Aldrees S, Dias AB, Mansure JJ, Santapau D, Garcia C, Saornil MA, Belfort Neto R, Burnier MN. Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma. Mod Pathol. 2018;31:1201-1210. [PMID: 29581543 DOI: 10.1038/s41379-018-0043-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
285 Saito H, Takaya S, Osaki T, Ikeguchi M. Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients. Gastric Cancer. 2013;16:473-479. [PMID: 23179366 DOI: 10.1007/s10120-012-0210-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
286 Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes. Cancer Sci 2020;111:3142-54. [PMID: 32536012 DOI: 10.1111/cas.14532] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
287 Nakano-Narusawa Y, Yokohira M, Yamakawa K, Ye J, Tanimoto M, Wu L, Mukai Y, Imaida K, Matsuda Y. Relationship between Lung Carcinogenesis and Chronic Inflammation in Rodents. Cancers (Basel) 2021;13:2910. [PMID: 34200786 DOI: 10.3390/cancers13122910] [Reference Citation Analysis]
288 Lin Z, Chen X, Li Z, Luo Y, Fang Z, Xu B, Han M. PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0160485. [PMID: 27483468 DOI: 10.1371/journal.pone.0160485] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
289 Xu YP, Lv L, Liu Y, Smith MD, Li WC, Tan XM, Cheng M, Li Z, Bovino M, Aubé J, Xiong Y. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. J Clin Invest 2019;129:4316-31. [PMID: 31310587 DOI: 10.1172/JCI129317] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 12.7] [Reference Citation Analysis]
290 Elster JD, Krishnadas DK, Lucas KG. Dendritic cell vaccines: A review of recent developments and their potential pediatric application. Hum Vaccin Immunother 2016;12:2232-9. [PMID: 27245943 DOI: 10.1080/21645515.2016.1179844] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
291 Lo Re G, Lo Re F, Doretto P, Del Conte A, Amadio M, Cozzi C, Casarotto MM, Maruzzi D, Marus W, Ubiali P, Sandri P. Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience. Cytokine 2019;113:50-60. [PMID: 29958796 DOI: 10.1016/j.cyto.2018.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
292 Jabbour SK, Berman AT, Simone CB 2nd. Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. Transl Lung Cancer Res 2017;6:113-8. [PMID: 28529894 DOI: 10.21037/tlcr.2017.04.02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
293 Hasegawa K, Ikeda Y, Kunugi Y, Kurosaki A, Imai Y, Kohyama S, Nagao S, Kozawa E, Yoshida K, Tsunoda T, Nakamura Y, Fujiwara K. Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer. Journal of Immunotherapy 2018;41:201-7. [DOI: 10.1097/cji.0000000000000214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
294 Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, Morris LG. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016;1:e89829. [PMID: 27777979 DOI: 10.1172/jci.insight.89829] [Cited by in Crossref: 283] [Cited by in F6Publishing: 263] [Article Influence: 47.2] [Reference Citation Analysis]
295 Roviello G, D’angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini ND, Sobhani N. Avelumab in gastric cancer. Immunotherapy 2019;11:759-68. [DOI: 10.2217/imt-2019-0011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
296 Bozorgmehr F, Chung I, Christopoulos P, Krisam J, Schneider MA, Brückner L, Mueller DW, Thomas M, Rieken S. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial. BMC Cancer 2020;20:806. [PMID: 32842974 DOI: 10.1186/s12885-020-07264-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
297 De Sousa Linhares A, Leitner J, Grabmeier-Pfistershammer K, Steinberger P. Not All Immune Checkpoints Are Created Equal. Front Immunol 2018;9:1909. [PMID: 30233564 DOI: 10.3389/fimmu.2018.01909] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 17.3] [Reference Citation Analysis]
298 Nelson CE, Mills LJ, McCurtain JL, Thompson EA, Seelig DM, Bhela S, Quarnstrom CF, Fife BT, Vezys V. Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells. Proc Natl Acad Sci U S A 2019;116:2640-5. [PMID: 30679280 DOI: 10.1073/pnas.1810326116] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
299 Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid 2012;7:93-103. [PMID: 23055947 DOI: 10.2147/CE.S29001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 24] [Article Influence: 0.5] [Reference Citation Analysis]
300 Zhao J, Meng Z, Xie C, Yang C, Liu Z, Wu S, Wang B, Fan P, Jin X, Wu H. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Int J Biochem Cell Biol 2019;108:84-91. [PMID: 30664982 DOI: 10.1016/j.biocel.2019.01.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
301 Li X, Lian Z, Wang S, Xing L, Yu J. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. Cancer Letters 2018;418:1-9. [DOI: 10.1016/j.canlet.2018.01.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
302 Li T, Jia D, Teng L. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study. Invest New Drugs 2020;38:1334-41. [DOI: 10.1007/s10637-020-00913-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
303 Deng H, Tan S, Gao X, Zou C, Xu C, Tu K, Song Q, Fan F, Huang W, Zhang Z. Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity. Acta Pharm Sin B 2020;10:358-73. [PMID: 32082979 DOI: 10.1016/j.apsb.2019.07.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
304 Chen DS, Hurwitz H. Combinations of Bevacizumab With Cancer Immunotherapy. Cancer J. 2018;24:193-204. [PMID: 30119083 DOI: 10.1097/ppo.0000000000000327] [Cited by in Crossref: 67] [Cited by in F6Publishing: 33] [Article Influence: 22.3] [Reference Citation Analysis]
305 Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity 2016;44:1255-69. [PMID: 27332730 DOI: 10.1016/j.immuni.2016.06.001] [Cited by in Crossref: 438] [Cited by in F6Publishing: 442] [Article Influence: 87.6] [Reference Citation Analysis]
306 O'Neill RE, Du W, Mohammadpour H, Alqassim E, Qiu J, Chen G, McCarthy PL, Lee KP, Cao X. T Cell-Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses. J Immunol 2017;199:3700-10. [PMID: 29046346 DOI: 10.4049/jimmunol.1700380] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
307 Xu H, Bratton L, Nead M, Russell D, Zhou Z. Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens. Cytojournal 2018;15:29. [PMID: 30662515 DOI: 10.4103/cytojournal.cytojournal_2_18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
308 Badiyan SN, Roach MC, Chuong MD, Rice SR, Onyeuku NE, Remick J, Chilukuri S, Glass E, Mohindra P, Simone CB 2nd. Combining immunotherapy with radiation therapy in thoracic oncology. J Thorac Dis 2018;10:S2492-507. [PMID: 30206494 DOI: 10.21037/jtd.2018.05.73] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
309 Glorieux C, Xia X, He YQ, Hu Y, Cremer K, Robert A, Liu J, Wang F, Ling J, Chiao PJ, Huang P. Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling. Redox Biol 2021;38:101780. [PMID: 33171331 DOI: 10.1016/j.redox.2020.101780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
310 Geng Q, Rohondia SO, Khan HJ, Jiao P, Dou QP. Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019). Expert Opin Ther Pat 2020;30:677-94. [PMID: 32715813 DOI: 10.1080/13543776.2020.1801640] [Reference Citation Analysis]
311 Lotfinejad P, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Jadidi Niaragh F, Safaei S, Asadi M, Baradaran B. PD-1/PD-L1 axis importance and tumor microenvironment immune cells. Life Sci 2020;259:118297. [PMID: 32822718 DOI: 10.1016/j.lfs.2020.118297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
312 Grassberger C, Ellsworth SG, Wilks MQ, Keane FK, Loeffler JS. Assessing the interactions between radiotherapy and antitumour immunity. Nat Rev Clin Oncol 2019;16:729-45. [PMID: 31243334 DOI: 10.1038/s41571-019-0238-9] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 20.7] [Reference Citation Analysis]
313 Haanen JB. Immunotherapy of melanoma. EJC Suppl 2013;11:97-105. [PMID: 26217118 DOI: 10.1016/j.ejcsup.2013.07.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
314 Jomrich G, Silberhumer GR, Marian B, Beer A, Müllauer L. Programmed death-ligand 1 expression in rectal cancer. Eur Surg 2016;48:352-6. [PMID: 28058043 DOI: 10.1007/s10353-016-0447-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
315 Joseph SA, Taglialatela A, Leuzzi G, Huang JW, Cuella-Martin R, Ciccia A. Time for remodeling: SNF2-family DNA translocases in replication fork metabolism and human disease. DNA Repair (Amst) 2020;95:102943. [PMID: 32971328 DOI: 10.1016/j.dnarep.2020.102943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
316 Guo Y, Wang Y, Han W. Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. J Immunol Res 2016;2016:3850839. [PMID: 26998495 DOI: 10.1155/2016/3850839] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
317 Xu J, Sun HH, Fletcher CD, Hornick JL, Morgan EA, Freeman GJ, Hodi FS, Pinkus GS, Rodig SJ. Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. American Journal of Surgical Pathology 2016;40:443-53. [DOI: 10.1097/pas.0000000000000590] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
318 Cao L, Wang X, Li S, Zhi Q, Wang Y, Wang L, Li K, Jiang R. PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level. J Cancer 2017;8:3251-60. [PMID: 29158797 DOI: 10.7150/jca.21118] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
319 Li LL, Yuan HL, Yang YQ, Wang L, Zou RC. A brief review concerning Chimeric Antigen Receptors T cell therapy. J Cancer 2020;11:5424-31. [PMID: 32742489 DOI: 10.7150/jca.46308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
320 Fisher R, Larkin J. Individualising treatment choices in a crowded treatment algorithm. EJC Suppl 2013;11:160-8. [PMID: 26217125 DOI: 10.1016/j.ejcsup.2013.07.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
321 He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol 2017;12:814-23. [PMID: 28132868 DOI: 10.1016/j.jtho.2017.01.019] [Cited by in Crossref: 74] [Cited by in F6Publishing: 87] [Article Influence: 14.8] [Reference Citation Analysis]
322 Jadus MR, Natividad J, Mai A, Ouyang Y, Lambrecht N, Szabo S, Ge L, Hoa N, Dacosta-Iyer MG. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol 2012;2012:160724. [PMID: 22899945 DOI: 10.1155/2012/160724] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
323 Schatton T, Scolyer RA, Thompson JF, Mihm MC Jr. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol 2014;1102:287-324. [PMID: 24258985 DOI: 10.1007/978-1-62703-727-3_16] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
324 Liao D, Wang M, Liao Y, Li J, Niu T. A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. Front Pharmacol 2019;10:609. [PMID: 31244654 DOI: 10.3389/fphar.2019.00609] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
325 Amini L, Greig J, Schmueck-Henneresse M, Volk HD, Bézie S, Reinke P, Guillonneau C, Wagner DL, Anegon I. Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications. Front Immunol 2020;11:611638. [PMID: 33717052 DOI: 10.3389/fimmu.2020.611638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
326 Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, Ajarim D, Al-Tweigeri T, Dermime S. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8:190-8. [PMID: 16611412 DOI: 10.1593/neo.05733] [Cited by in Crossref: 379] [Cited by in F6Publishing: 385] [Article Influence: 23.7] [Reference Citation Analysis]
327 Ørskov AD, Treppendahl MB, Skovbo A, Holm MS, Friis LS, Hokland M, Grønbæk K. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 2015;6:9612-26. [PMID: 25823822 DOI: 10.18632/oncotarget.3324] [Cited by in Crossref: 109] [Cited by in F6Publishing: 108] [Article Influence: 18.2] [Reference Citation Analysis]
328 Lafon M. Evasive strategies in rabies virus infection. Adv Virus Res 2011;79:33-53. [PMID: 21601041 DOI: 10.1016/B978-0-12-387040-7.00003-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 30] [Article Influence: 5.9] [Reference Citation Analysis]
329 Jiang H, Cui N, Yang L, Liu C, Yue L, Guo L, Wang H, Shao Z. Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes. Oncotarget 2017;8:98270-9. [PMID: 29228688 DOI: 10.18632/oncotarget.21548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
330 Lv Z, Feng HY, Tao W, Li HZ, Zhang X. CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates. Front Oncol 2021;11:744107. [PMID: 34956870 DOI: 10.3389/fonc.2021.744107] [Reference Citation Analysis]
331 Li Z, Chen L, Rubinstein MP. Cancer immunotherapy: are we there yet? Exp Hematol Oncol 2013;2:33. [PMID: 24326015 DOI: 10.1186/2162-3619-2-33] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
332 Saudemont A, Jouy N, Hetuin D, Quesnel B. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 2005;105:2428-35. [DOI: 10.1182/blood-2004-09-3458] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 5.4] [Reference Citation Analysis]
333 Fu G, Polyakova O, MacMillan C, Ralhan R, Walfish PG. Programmed Death - Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features. EBioMedicine 2017;18:50-5. [PMID: 28363612 DOI: 10.1016/j.ebiom.2017.03.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
334 Xu S, Sharma UC, Tuttle C, Pokharel S. Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. Front Cardiovasc Med 2021;8:619650. [PMID: 33614750 DOI: 10.3389/fcvm.2021.619650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
335 Choi BBR, Choi JH, Kim UK, Hwang DS, Kim GC. Gold nanoparticles conjugated with programmed death-ligand 1 antibodies induce apoptosis of SCC-25 oral squamous cell carcinoma cells via programmed death-ligand 1/signal transducer and transcription 3 pathway. Arch Oral Biol 2021;125:105085. [PMID: 33667957 DOI: 10.1016/j.archoralbio.2021.105085] [Reference Citation Analysis]
336 Kong X, Zhang Q, Lai Y, Hu H, Chen X, Hu Y. Global patent landscape of programmed cell death 1: implications of the rapid expansion. Expert Opinion on Therapeutic Patents 2018;28:69-80. [DOI: 10.1080/13543776.2017.1378349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
337 Sudo S, Kajiya H, Okano S, Sasaki M, Katsumata Y, Ohno J, Ikebe T, Hiraki A, Okabe K. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma. Cancer Sci 2020;111:1113-23. [PMID: 32012401 DOI: 10.1111/cas.14336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
338 Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA. 2006;103:10391-10396. [PMID: 16798883 DOI: 10.1073/pnas.0600937103] [Cited by in Crossref: 222] [Cited by in F6Publishing: 199] [Article Influence: 13.9] [Reference Citation Analysis]
339 Park JA, Cheung NV. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. J Hematol Oncol 2020;13:172. [PMID: 33303017 DOI: 10.1186/s13045-020-01012-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
340 Arneth B. Tumor Microenvironment. Medicina (Kaunas) 2019;56:E15. [PMID: 31906017 DOI: 10.3390/medicina56010015] [Cited by in Crossref: 61] [Cited by in F6Publishing: 70] [Article Influence: 20.3] [Reference Citation Analysis]
341 Eichhorn F, Harms A, Warth A, Muley T, Winter H, Eichhorn ME. PD-L1 expression in large cell neuroendocrine carcinoma of the lung. Lung Cancer 2018;118:76-82. [PMID: 29572007 DOI: 10.1016/j.lungcan.2018.02.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
342 Wang T, Wu X, Guo C, Zhang K, Xu J, Li Z, Jiang S. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. J Med Chem 2019;62:1715-30. [PMID: 30247903 DOI: 10.1021/acs.jmedchem.8b00990] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
343 Gyori D, Lim EL, Grant FM, Spensberger D, Roychoudhuri R, Shuttleworth SJ, Okkenhaug K, Stephens LR, Hawkins PT. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy. JCI Insight 2018;3:120631. [PMID: 29875321 DOI: 10.1172/jci.insight.120631] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
344 Adel-Khattab D, Groeger S, Domann E, Chakraborty T, Lochnit G, Meyle J. Porphyromonas gingivalis induced up-regulation of PD-L1 in colon carcinoma cells. Mol Oral Microbiol 2021;36:172-81. [PMID: 33715305 DOI: 10.1111/omi.12332] [Reference Citation Analysis]
345 Girotti MR, Saturno G, Lorigan P, Marais R. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. Mol Oncol 2014;8:1140-58. [PMID: 25178978 DOI: 10.1016/j.molonc.2014.07.027] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
346 Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167:671-686. [PMID: 29063313 DOI: 10.1007/s10549-017-4537-5] [Cited by in Crossref: 256] [Cited by in F6Publishing: 259] [Article Influence: 51.2] [Reference Citation Analysis]
347 Santos G, Nikolov S, Lai X, Eberhardt M, Dreyer FS, Paul S, Schuler G, Vera J. Model-based genotype-phenotype mapping used to investigate gene signatures of immune sensitivity and resistance in melanoma micrometastasis. Sci Rep 2016;6:24967. [PMID: 27113331 DOI: 10.1038/srep24967] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
348 Zhang L, Yu JS. Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines. J Neurooncol 2019;143:429-36. [PMID: 31152305 DOI: 10.1007/s11060-019-03193-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
349 Messeha SS, Zarmouh NO, Soliman KFA. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Nutrients 2021;13:1718. [PMID: 34069461 DOI: 10.3390/nu13051718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
350 Koh SA. An update on immunotherapy with PD-1 and PD-L1 blockade. Yeungnam Univ J Med 2021. [PMID: 34496466 DOI: 10.12701/yujm.2021.01312] [Reference Citation Analysis]
351 Morimoto Y, Kishida T, Kotani S, Takayama K, Mazda O. Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. Biochemical and Biophysical Research Communications 2018;507:330-6. [DOI: 10.1016/j.bbrc.2018.11.035] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
352 Tsuyuki Y, Ishikawa E, Kohno K, Shimada K, Ohka F, Suzuki Y, Mabuchi S, Satou A, Takahara T, Kato S, Miyagi S, Ozawa H, Kawano T, Takagi Y, Hiraga J, Wakabayashi T, Nakamura S. Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system. Neuropathology 2021;41:99-108. [PMID: 33269495 DOI: 10.1111/neup.12705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
353 D'Aiello A, Lin J, Gucalp R, Tabatabaie V, Cheng H, Bloomgarden NA, Tomer Y, Halmos B. Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort. Cancers (Basel) 2021;13:1464. [PMID: 33806774 DOI: 10.3390/cancers13061464] [Reference Citation Analysis]
354 Martin L, Zoubir M, Le Tourneau C. [Recurrence of upper aerodigestive tract tumors]. Bull Cancer 2014;101:511-20. [PMID: 24886903 DOI: 10.1684/bdc.2014.1970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
355 Beswick EJ, Johnson JR, Saada JI, Humen M, House J, Dann S, Qiu S, Brasier AR, Powell DW, Reyes VE, Pinchuk IV. TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+ stromal cells. J Immunol 2014;193:2218-29. [PMID: 25070848 DOI: 10.4049/jimmunol.1203441] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
356 Zhang W, Wang S, Gu J, Gao Y, Wang Z, Zhang K, Mu N, Huang T, Li W, Hao Q, Xue X, Zhang W, Zhang Y, Zhang C. Synergistic tumoricidal effect of combined hPD-L1 vaccine and HER2 gene vaccine. Biochemical and Biophysical Research Communications 2018;497:394-400. [DOI: 10.1016/j.bbrc.2018.02.092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
357 Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41-53. [PMID: 23667165 DOI: 10.1189/jlb.1212631] [Cited by in Crossref: 206] [Cited by in F6Publishing: 192] [Article Influence: 22.9] [Reference Citation Analysis]
358 Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One. 2015;10:e0130142. [PMID: 26086854 DOI: 10.1371/journal.pone.0130142] [Cited by in Crossref: 294] [Cited by in F6Publishing: 283] [Article Influence: 42.0] [Reference Citation Analysis]
359 Pai SI, Faquin WC. Programmed cell death ligand 1 as a biomarker in head and neck cancer. Cancer Cytopathol 2017;125:529-33. [PMID: 28472542 DOI: 10.1002/cncy.21872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
360 Khazen R, Müller S, Gaudenzio N, Espinosa E, Puissegur MP, Valitutti S. Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse. Nat Commun 2016;7:10823. [PMID: 26940455 DOI: 10.1038/ncomms10823] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
361 Joshi K, Chain BM, Peggs KS, Quezada SA. The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. Cold Spring Harb Perspect Med 2018;8:a027086. [PMID: 28630228 DOI: 10.1101/cshperspect.a027086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
362 Chen L, Zhang Z, Chen W, Zhang Z, Li Y, Shi M, Zhang J, Chen L, Wang S, Wang FS. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol. 2007;178:6634-6641. [PMID: 17475895 DOI: 10.4049/jimmunol.178.10.6634] [Cited by in Crossref: 93] [Cited by in F6Publishing: 93] [Article Influence: 6.2] [Reference Citation Analysis]
363 Dobrzanski MJ. Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol 2013;3:63. [PMID: 23533029 DOI: 10.3389/fonc.2013.00063] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 6.1] [Reference Citation Analysis]
364 Liu F, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005;5:29-41. [DOI: 10.1038/nrc1527] [Cited by in Crossref: 970] [Cited by in F6Publishing: 901] [Article Influence: 57.1] [Reference Citation Analysis]
365 Kongtawelert P, Wudtiwai B, Shwe TH, Pothacharoen P, Phitak T. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin. Int Immunopharmacol 2020;86:106759. [PMID: 32663768 DOI: 10.1016/j.intimp.2020.106759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
366 Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017;8:1597. [PMID: 29255458 DOI: 10.3389/fimmu.2017.01597] [Cited by in Crossref: 116] [Cited by in F6Publishing: 114] [Article Influence: 23.2] [Reference Citation Analysis]
367 Tannock I, Joshua A. Purchasing silence. Annals of Oncology 2018;29:1339-40. [DOI: 10.1093/annonc/mdy131] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
368 Ochoa de Olza M, Oliva M, Hierro C, Matos I, Martin-Liberal J, Garralda E. Early-drug development in the era of immuno-oncology: are we ready to face the challenges? Ann Oncol 2018;29:1727-40. [PMID: 29945232 DOI: 10.1093/annonc/mdy225] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
369 Zhou J, Kang N, Cui L, Ba D, He W. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Cell Mol Immunol 2012;9:34-44. [PMID: 21666706 DOI: 10.1038/cmi.2011.16] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
370 Yajima T, Hoshino K, Muranushi R, Mogi A, Onozato R, Yamaki E, Kosaka T, Tanaka S, Shirabe K, Yoshikai Y, Kuwano H. Fas/FasL signaling is critical for the survival of exhausted antigen-specific CD8+ T cells during tumor immune response. Mol Immunol 2019;107:97-105. [PMID: 30711908 DOI: 10.1016/j.molimm.2019.01.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
371 Ying H, Zhang X, Duan Y, Lao M, Xu J, Yang H, Liang T, Bai X. Non-cytomembrane PD-L1: An atypical target for cancer. Pharmacol Res 2021;170:105741. [PMID: 34174446 DOI: 10.1016/j.phrs.2021.105741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Joosse ME, Nederlof I, Walker LSK, Samsom JN. Tipping the balance: inhibitory checkpoints in intestinal homeostasis. Mucosal Immunol 2019;12:21-35. [PMID: 30498201 DOI: 10.1038/s41385-018-0113-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
373 Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537-1544. [PMID: 19423728 DOI: 10.1182/blood-2008-12-195792] [Cited by in Crossref: 964] [Cited by in F6Publishing: 910] [Article Influence: 74.2] [Reference Citation Analysis]
374 Woods K, Knights AJ, Anaka M, Schittenhelm RB, Purcell AW, Behren A, Cebon J. Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma. J Immunother Cancer 2016;4:10. [PMID: 26885372 DOI: 10.1186/s40425-016-0111-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
375 Murali AK, Mehrotra S. Apoptosis - an Ubiquitous T cell Immunomodulator. J Clin Cell Immunol 2011;S3:2. [PMID: 23504027 DOI: 10.4172/2155-9899.S3-002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
376 Huang X, Xie X, Wang H, Xiao X, Yang L, Tian Z, Guo X, Zhang L, Tang H, Xie X. PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a. J Exp Clin Cancer Res 2017;36:129. [PMID: 28915924 DOI: 10.1186/s13046-017-0593-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
377 Lim JCT, Yeong JPS, Lim CJ, Ong CCH, Wong SC, Chew VSP, Ahmed SS, Tan PH, Iqbal J. An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use. Pathology 2018;50:333-41. [PMID: 29429740 DOI: 10.1016/j.pathol.2017.11.087] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
378 Inaguma S, Wang Z, Lasota J, Sarlomo-Rikala M, McCue PA, Ikeda H, Miettinen M. Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors. Am J Surg Pathol 2016;40:1133-42. [PMID: 27158757 DOI: 10.1097/PAS.0000000000000653] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
379 Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682-8. [PMID: 20373055 DOI: 10.1007/s12032-010-9515-2] [Cited by in Crossref: 367] [Cited by in F6Publishing: 385] [Article Influence: 30.6] [Reference Citation Analysis]
380 McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016;2:46-54. [PMID: 26562159 DOI: 10.1001/jamaoncol.2015.3638] [Cited by in Crossref: 431] [Cited by in F6Publishing: 460] [Article Influence: 71.8] [Reference Citation Analysis]
381 Fan P, Zhao J, Meng Z, Wu H, Wang B, Wu H, Jin X. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. J Exp Clin Cancer Res 2019;38:47. [PMID: 30709380 DOI: 10.1186/s13046-019-1044-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
382 Seliger B, Quandt D. The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother 2012;61:1327-41. [DOI: 10.1007/s00262-012-1293-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
383 Gustafson MP, DiCostanzo AC, Wheatley CM, Kim CH, Bornschlegl S, Gastineau DA, Johnson BD, Dietz AB. A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood. J Immunother Cancer 2017;5:30. [PMID: 28428879 DOI: 10.1186/s40425-017-0231-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
384 Hira-Miyazawa M, Nakamura H, Hirai M, Kobayashi Y, Kitahara H, Bou-Gharios G, Kawashiri S. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. Int J Oncol 2018;52:379-88. [PMID: 29345283 DOI: 10.3892/ijo.2017.4221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
385 Li S, Liao W, Chen M, Shan S, Song Y, Zhang S, Song H, Yuan Z. Expression of Programmed Death-1 (PD-1) on CD4+ and CD8+ T cells in Rheumatoid Arthritis. Inflammation 2014;37:116-21. [DOI: 10.1007/s10753-013-9718-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
386 Tamiya M, Tamiya A, Hosoya K, Taniguchi Y, Yokoyama T, Fukuda Y, Hirano K, Matsumoto H, Kominami R, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Kinoshita Y, Hara S, Kumagai T, Fujimoto D. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). Invest New Drugs 2019;37:1266-73. [PMID: 31392549 DOI: 10.1007/s10637-019-00843-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
387 Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol 2018;93:953-62. [DOI: 10.1002/ajh.25112] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
388 Ramamurthy C, Godwin JL, Borghaei H. Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose? Curr Treat Options Oncol 2017;18:33. [PMID: 28534248 DOI: 10.1007/s11864-017-0476-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
389 Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett 2018;195:76-82. [PMID: 29307688 DOI: 10.1016/j.imlet.2018.01.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
390 Khair DO, Bax HJ, Mele S, Crescioli S, Pellizzari G, Khiabany A, Nakamura M, Harris RJ, French E, Hoffmann RM, Williams IP, Cheung A, Thair B, Beales CT, Touizer E, Signell AW, Tasnova NL, Spicer JF, Josephs DH, Geh JL, MacKenzie Ross A, Healy C, Papa S, Lacy KE, Karagiannis SN. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Front Immunol 2019;10:453. [PMID: 30941125 DOI: 10.3389/fimmu.2019.00453] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 29.3] [Reference Citation Analysis]
391 Zheng Z, Sun R, Zhao HJ, Fu D, Zhong HJ, Weng XQ, Qu B, Zhao Y, Wang L, Zhao WL. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Mol Cancer 2019;18:54. [PMID: 30925928 DOI: 10.1186/s12943-019-0977-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
392 Heigener D, Reck M. Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. Expert Rev Anticancer Ther 2015;15:69-83. [PMID: 25199617 DOI: 10.1586/14737140.2015.957187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
393 Gardiner RE, Jahangeer S, Forde P, Ariffin AB, Bird B, Soden D, Hinchion J. Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role? Cancer Metastasis Rev 2015;34:129-44. [PMID: 25726003 DOI: 10.1007/s10555-015-9550-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
394 Wu Y, Zhang C, Liu X, He Z, Shan B, Zeng Q, Zhao Q, Zhu H, Liao H, Cen X, Xu X, Zhang M, Hou T, Wang Z, Yan H, Yang S, Sun Y, Chen Y, Wu R, Xie T, Chen W, Najafov A, Ying S, Xia H. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. Nat Commun 2021;12:2346. [PMID: 33879767 DOI: 10.1038/s41467-021-22467-8] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
395 Hori J, Wang M, Miyashita M, Tanemoto K, Takahashi H, Takemori T, Okumura K, Yagita H, Azuma M. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol. 2006;177:5928-5935. [PMID: 17056517 DOI: 10.4049/jimmunol.177.9.5928] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 8.9] [Reference Citation Analysis]
396 Hu T, Wolfram J, Srivastava S. Extracellular Vesicles in Cancer Detection: Hopes and Hypes. Trends Cancer 2021;7:122-33. [PMID: 33008796 DOI: 10.1016/j.trecan.2020.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
397 Jiang Z, Chen Y, Feng X, Jiang J, Chen T, Xie H, Zhou L, Zheng S. Hepatic stellate cells promote immunotolerance following orthotopic liver transplantation in rats via induction of T cell apoptosis and regulation of Th2/Th3-like cell cytokine production. Exp Ther Med 2013;5:165-9. [PMID: 23251260 DOI: 10.3892/etm.2012.801] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
398 Hude I, Sasse S, Engert A, Bröckelmann PJ. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica 2017;102:30-42. [PMID: 27884973 DOI: 10.3324/haematol.2016.150656] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
399 Banerji S, Meyers DE, Harlos C, Dawe DE. The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma. Curr Oncol 2021;28:4542-51. [PMID: 34898559 DOI: 10.3390/curroncol28060385] [Reference Citation Analysis]
400 Sasidharan Nair V, Toor SM, Ali BR, Elkord E. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. Expert Opin Ther Targets. 2018;22:547-557. [PMID: 29702007 DOI: 10.1080/14728222.2018.1471137] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
401 Teramoto K, Igarashi T, Kataoka Y, Ishida M, Hanaoka J, Sumimoto H, Daigo Y. Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer. Cancer Immunol Immunother 2021;70:1063-74. [PMID: 33113005 DOI: 10.1007/s00262-020-02755-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
402 Saigusa S, Toiyama Y, Tanaka K, Inoue Y, Mori K, Ide S, Imaoka H, Kawamura M, Mohri Y, Kusunoki M. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. Int J Clin Oncol 2016;21:946-52. [PMID: 26919982 DOI: 10.1007/s10147-016-0962-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
403 Liu D, Badeti S, Dotti G, Jiang JG, Wang H, Dermody J, Soteropoulos P, Streck D, Birge RB, Liu C. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. Cell Commun Signal 2020;18:134. [PMID: 32843053 DOI: 10.1186/s12964-020-00617-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
404 Ramelyte E, Schindler SA, Dummer R. The safety of anti PD-1 therapeutics for the treatment of melanoma. Expert Opin Drug Saf 2017;16:41-53. [PMID: 27737598 DOI: 10.1080/14740338.2016.1248402] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
405 Niogret J, Berger H, Rebe C, Mary R, Ballot E, Truntzer C, Thibaudin M, Derangère V, Hibos C, Hampe L, Rageot D, Accogli T, Joubert P, Routy B, Harker J, Vegran F, Ghiringhelli F, Chalmin F. Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. J Immunother Cancer 2021;9:e002157. [PMID: 34103351 DOI: 10.1136/jitc-2020-002157] [Reference Citation Analysis]
406 Dietsch GN. Motolimod effectively drives immune activation in advanced cancer patients. Oncoimmunology 2016;5:e1126037. [PMID: 27467937 DOI: 10.1080/2162402X.2015.1126037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
407 Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Huang TH, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell 2018;33:187-201.e10. [PMID: 29438695 DOI: 10.1016/j.ccell.2018.01.009] [Cited by in Crossref: 160] [Cited by in F6Publishing: 155] [Article Influence: 40.0] [Reference Citation Analysis]
408 Cubillos-Zapata C, Avendaño-Ortiz J, Hernandez-Jimenez E, Toledano V, Casas-Martin J, Varela-Serrano A, Torres M, Almendros I, Casitas R, Fernández-Navarro I, Garcia-Sanchez A, Aguirre LA, Farre R, López-Collazo E, García-Rio F. Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea. Eur Respir J 2017;50:1700833. [PMID: 29051270 DOI: 10.1183/13993003.00833-2017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
409 Hurez V, Padrón ÁS, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol 2017;187:53-63. [PMID: 27690272 DOI: 10.1111/cei.12875] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
410 Okazaki T, Okazaki IM. Stimulatory and Inhibitory Co-signals in Autoimmunity. Adv Exp Med Biol 2019;1189:213-32. [PMID: 31758536 DOI: 10.1007/978-981-32-9717-3_8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
411 Safaei HR, Rostamzadeh A, Rahmani O, Mohammadi M, Ghaderi O, Yahaghi H, Ahmadi K. Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma. Tumour Biol 2016;37:7583-7. [PMID: 26687644 DOI: 10.1007/s13277-015-4652-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
412 Ren D, Hua Y, Yu B, Ye X, He Z, Li C, Wang J, Mo Y, Wei X, Chen Y, Zhou Y, Liao Q, Wang H, Xiang B, Zhou M, Li X, Li G, Li Y, Zeng Z, Xiong W. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer 2020;19:19. [PMID: 32000802 DOI: 10.1186/s12943-020-1144-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 25.5] [Reference Citation Analysis]
413 MacFarlane AW 4th, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2014;2:320-31. [PMID: 24764579 DOI: 10.1158/2326-6066.CIR-13-0133] [Cited by in Crossref: 92] [Cited by in F6Publishing: 72] [Article Influence: 10.2] [Reference Citation Analysis]
414 Chaudhri A, Xiao Y, Klee AN, Wang X, Zhu B, Freeman GJ. PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface. Cancer Immunol Res 2018;6:921-9. [PMID: 29871885 DOI: 10.1158/2326-6066.CIR-17-0316] [Cited by in Crossref: 61] [Cited by in F6Publishing: 40] [Article Influence: 15.3] [Reference Citation Analysis]
415 Meyers DE, Bryan PM, Banerji S, Morris DG. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. Curr Oncol 2018;25:e324-34. [PMID: 30111979 DOI: 10.3747/co.25.3976] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
416 Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature 2017;541:321-30. [DOI: 10.1038/nature21349] [Reference Citation Analysis]
417 Razavi SM, Lee KE, Jin BE, Aujla PS, Gholamin S, Li G. Immune Evasion Strategies of Glioblastoma. Front Surg 2016;3:11. [PMID: 26973839 DOI: 10.3389/fsurg.2016.00011] [Cited by in Crossref: 112] [Cited by in F6Publishing: 116] [Article Influence: 18.7] [Reference Citation Analysis]
418 Wang K, He H. Pancreatic Tumor Microenvironment. Adv Exp Med Biol 2020;1296:243-57. [PMID: 34185297 DOI: 10.1007/978-3-030-59038-3_15] [Reference Citation Analysis]
419 Menon H, Ramapriyan R, Cushman TR, Verma V, Kim HH, Schoenhals JE, Atalar C, Selek U, Chun SG, Chang JY, Barsoumian HB, Nguyen QN, Altan M, Cortez MA, Hahn SM, Welsh JW. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front Immunol 2019;10:193. [PMID: 30828330 DOI: 10.3389/fimmu.2019.00193] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 16.0] [Reference Citation Analysis]
420 Simone R, Floriani A, Saverino D. Stimulation of human CD4⁺ T lymphocytes via TLR3, TLR5 and TLR7/8 up-regulates expression of costimulatory and modulates proliferation. Open Microbiol J 2009;3:1-8. [PMID: 19294011 DOI: 10.2174/1874285800903010001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
421 Chen SC, Chang PM, Wang HJ, Tai SK, Chu PY, Yang MH. PD-L1 expression is associated with p16INK4A expression in non-oropharyngeal head and neck squamous cell carcinoma. Oncol Lett 2018;15:2259-65. [PMID: 29434933 DOI: 10.3892/ol.2017.7564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
422 Sckisel GD, Mirsoian A, Minnar CM, Crittenden M, Curti B, Chen JQ, Blazar BR, Borowsky AD, Monjazeb AM, Murphy WJ. Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy. J Immunother Cancer 2017;5:33. [PMID: 28428882 DOI: 10.1186/s40425-017-0235-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
423 Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, Taniguchi H, Sasaki Y, Kurita D, Kawamoto K, Kato K, Imaizumi Y, Seto M, Ohshima K. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood 2016;128:1374-81. [PMID: 27418641 DOI: 10.1182/blood-2016-02-698936] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 13.8] [Reference Citation Analysis]
424 Monaghan SF, Thakkar RK, Heffernan DS, Huang X, Chung CS, Lomas-Neira J, Cioffi WG, Ayala A. Mechanisms of indirect acute lung injury: a novel role for the coinhibitory receptor, programmed death-1. Ann Surg 2012;255:158-64. [PMID: 21997806 DOI: 10.1097/SLA.0b013e31823433ca] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
425 Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, Fukushima T, Akiba H, Yagita H, Okumura K. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol. 2003;171:4156-4163. [PMID: 14530338 DOI: 10.4049/jimmunol.171.8.4156] [Cited by in Crossref: 121] [Cited by in F6Publishing: 118] [Article Influence: 6.7] [Reference Citation Analysis]
426 Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol. 2014;25:2433-2442. [PMID: 25223485 DOI: 10.1093/annonc/mdu452] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 10.8] [Reference Citation Analysis]
427 Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20212-20217. [PMID: 24277834 DOI: 10.1073/pnas.1320318110] [Cited by in Crossref: 849] [Cited by in F6Publishing: 841] [Article Influence: 94.3] [Reference Citation Analysis]
428 Qian C, Guo H, Chen X, Shi A, Li S, Wang X, Pan J, Fang C. Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility. J Diabetes Res 2018;2018:1614683. [PMID: 30534571 DOI: 10.1155/2018/1614683] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
429 Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, Lybeck H, Kim MM, Lybeck M, Reid TR. No patient left behind: The promise of immune priming with epigenetic agents. Oncoimmunology 2017;6:e1315486. [PMID: 29123948 DOI: 10.1080/2162402X.2017.1315486] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
430 Pavlick AC, Fecher L, Ascierto PA, Sullivan RJ. Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer? Am Soc Clin Oncol Educ Book 2019;39:564-71. [PMID: 31099689 DOI: 10.1200/EDBK_243071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
431 Yang J, He X, Lv Q, Jing J, Shi H. Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Front Pharmacol 2019;10:726. [PMID: 31312140 DOI: 10.3389/fphar.2019.00726] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
432 An HJ, Ko GH, Lee JH, Lee JS, Kim DC, Yang JW, Kim MH, Kim JP, Jung EJ, Song DH. Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma. J Pathol Transl Med 2018;52:9-13. [PMID: 28994272 DOI: 10.4132/jptm.2017.07.26] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
433 Quandt D, Jasinski-Bergner S, Müller U, Schulze B, Seliger B. Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. J Transl Med 2014;12:151. [PMID: 24885059 DOI: 10.1186/1479-5876-12-151] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
434 Barua A, Edassery SL, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Luborsky JL. Prevalence of antitumor antibodies in laying hen model of human ovarian cancer. Int J Gynecol Cancer 2009;19:500-7. [PMID: 19509543 DOI: 10.1111/IGC.0b013e3181a39db1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
435 Jabri B, Abadie V. IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. Nat Rev Immunol 2015;15:771-83. [PMID: 26567920 DOI: 10.1038/nri3919] [Cited by in Crossref: 139] [Cited by in F6Publishing: 132] [Article Influence: 19.9] [Reference Citation Analysis]
436 Zhang GQ, Wei WJ, Song HJ, Sun ZK, Shen CT, Zhang XY, Chen XY, Qiu ZL, Luo QY. PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER. Endocr Pract 2019;25:279-86. [PMID: 30913016 DOI: 10.4158/EP-2018-0342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
437 Charles E, Joshi S, Ash JD, Fox BA, Farris AD, Bzik DJ, Lang ML, Blader IJ. CD4 T-cell suppression by cells from Toxoplasma gondii-infected retinas is mediated by surface protein PD-L1. Infect Immun 2010;78:3484-92. [PMID: 20498261 DOI: 10.1128/IAI.00117-10] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
438 Liu W, Zhang L, Xiu Z, Guo J, Wang L, Zhou Y, Jiao Y, Sun M, Cai J. Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer. Onco Targets Ther 2020;13:7229-41. [PMID: 32801752 DOI: 10.2147/OTT.S255491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
439 Garcia-Bates TM, Palma ML, Shen C, Gambotto A, Macatangay BJC, Ferris RL, Rinaldo CR, Mailliard RB. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions. J Virol 2019;93:e02035-18. [PMID: 30541848 DOI: 10.1128/JVI.02035-18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
440 Shao Z, Wang AZ, George DJ, Zhang T. Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. Asian J Urol 2016;3:268-77. [PMID: 29264195 DOI: 10.1016/j.ajur.2016.08.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
441 Song Q, Shi F, Xiao S, Li Y, Zhao Y, Chang H. The integration of proportion and cell counts of stromal, not intratumoral, PD-1+ tumor-infiltrating lymphocytes has prognostic significance in esophageal squamous cell carcinoma. Dis Esophagus 2021;34:doaa035. [PMID: 32395761 DOI: 10.1093/dote/doaa035] [Reference Citation Analysis]
442 Tao J, Dai J, Hou S. Association between B7-H1 and cervical cancer: B7-H1 impairs the immune response in human cervical cancer cells. Exp Ther Med 2017;14:4125-33. [PMID: 29104629 DOI: 10.3892/etm.2017.5100] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
443 Ren HT, Li YM, Wang XJ, Kang HF, Jin TB, Ma XB, Liu XH, Wang M, Liu K, Xu P, Yao QL, Dai ZJ. PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women: A Hospital-Based Observational Study. Medicine (Baltimore) 2016;95:e3760. [PMID: 27227944 DOI: 10.1097/MD.0000000000003760] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
444 Lina TT, Alzahrani S, House J, Yamaoka Y, Sharpe AH, Rampy BA, Pinchuk IV, Reyes VE. Helicobacter pylori cag pathogenicity island's role in B7-H1 induction and immune evasion. PLoS One 2015;10:e0121841. [PMID: 25807464 DOI: 10.1371/journal.pone.0121841] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
445 Zhang J, Cao D, Yu S, Chen L, Wei D, Shen C, Zhuang L, Wang Q, Xu X, Tong Y. Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation. BMC Cancer 2018;18:467. [PMID: 29695237 DOI: 10.1186/s12885-018-4266-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
446 Meng J, Peng J, Feng J, Maurer J, Li X, Li Y, Yao S, Chu R, Pan X, Li J, Zhang T, Liu L, Zhang Q, Yuan Z, Bu H, Song K, Kong B. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. J Transl Med 2021;19:415. [PMID: 34620163 DOI: 10.1186/s12967-021-03073-0] [Reference Citation Analysis]
447 Kravtsova-Ivantsiv Y, Goldhirsh G, Ivantsiv A, Ben Itzhak O, Kwon YT, Pikarsky E, Ciechanover A. Excess of the NF-ĸB p50 subunit generated by the ubiquitin ligase KPC1 suppresses tumors via PD-L1- and chemokines-mediated mechanisms. Proc Natl Acad Sci U S A 2020;117:29823-31. [PMID: 33168738 DOI: 10.1073/pnas.2019604117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
448 Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med 2014;7:357-65. [PMID: 25484597 DOI: 10.2147/PGPM.S53163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 40] [Article Influence: 1.1] [Reference Citation Analysis]
449 Chuang J, Chao J, Hendifar A, Klempner SJ, Gong J. Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. Transl Gastroenterol Hepatol 2019;4:63. [PMID: 31559344 DOI: 10.21037/tgh.2019.08.04] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
450 Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, Kim JH, Choe JH, Shin JH, Hahn SY, Oh YL, Chung JH. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 2017;24:97-106. [PMID: 28093480 DOI: 10.1530/ERC-16-0421] [Cited by in Crossref: 61] [Cited by in F6Publishing: 37] [Article Influence: 15.3] [Reference Citation Analysis]
451 Hotchkiss RS, Colston E, Yende S, Crouser ED, Martin GS, Albertson T, Bartz RR, Brakenridge SC, Delano MJ, Park PK, Donnino MW, Tidswell M, Mayr FB, Angus DC, Coopersmith CM, Moldawer LL, Catlett IM, Girgis IG, Ye J, Grasela DM. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med 2019;45:1360-71. [PMID: 31576433 DOI: 10.1007/s00134-019-05704-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 15.0] [Reference Citation Analysis]
452 Patel P, Schutzer SE, Pyrsopoulos N. Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol 2016; 7(3): 242-255 [PMID: 27574562 DOI: 10.4291/wjgp.v7.i3.242] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
453 Spain L, Younger E, Hatipoglu E, Larkin J. Pembrolizumab in the management of metastatic melanoma. Melanoma Manag 2015;2:315-25. [PMID: 30190860 DOI: 10.2217/mmt.15.33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
454 Fan J, Feng Y, Tao Z, Chen J, Yang H, Shi Q, Li Z, She T, Li H, Jin Y, Cheng J, Lu X. A versatile platform for the tumor-targeted delivery of immune checkpoint-blocking immunoglobin G. J Control Release 2021;340:243-58. [PMID: 34752799 DOI: 10.1016/j.jconrel.2021.11.003] [Reference Citation Analysis]
455 Bandyopadhyay S, Quinn TJ, Scandiuzzi L, Basu I, Partanen A, Tomé WA, Macian F, Guha C. Low-Intensity Focused Ultrasound Induces Reversal of Tumor-Induced T Cell Tolerance and Prevents Immune Escape. J Immunol 2016;196:1964-76. [PMID: 26755821 DOI: 10.4049/jimmunol.1500541] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
456 Kunitomi H, Banno K, Yanokura M, Takeda T, Iijima M, Nakamura K, Iida M, Adachi M, Watanabe K, Matoba Y, Kobayashi Y, Tominaga E, Aoki D. New use of microsatellite instability analysis in endometrial cancer. Oncol Lett 2017;14:3297-301. [PMID: 28927079 DOI: 10.3892/ol.2017.6640] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
457 Khanna V, Kim H, Zhang W, Larson P, Shah M, Griffith TS, Ferguson D, Panyam J. Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). Sci Rep 2021;11:3346. [PMID: 33558639 DOI: 10.1038/s41598-021-83005-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
458 Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, Simko JP, Waldman FM, Pieper RO, Parsa AT. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene. 2009;28:306-312. [PMID: 18850006 DOI: 10.1038/onc.2008.384] [Cited by in Crossref: 109] [Cited by in F6Publishing: 105] [Article Influence: 7.8] [Reference Citation Analysis]
459 Zhang J, Quadri S, Wolfgang CL, Zheng L. New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines 2018;6:E87. [PMID: 30104497 DOI: 10.3390/biomedicines6030087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
460 Nakayama Y, Mimura K, Kua L, Okayama H, Min AKT, Saito K, Hanayama H, Watanabe Y, Saito M, Momma T, Saze Z, Ohki S, Suzuki Y, Ichikawa D, Yong W, Kono K. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. Gastric Cancer 2020;23:961-73. [DOI: 10.1007/s10120-020-01079-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
461 Harshman LC, Drake CG, Choueiri TK. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014;2:1132-41. [PMID: 25480555 DOI: 10.1158/2326-6066.CIR-14-0193] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 4.1] [Reference Citation Analysis]
462 Arens R, Scheeren FA. Genetic Screening for Novel Regulators of Immune Checkpoint Molecules. Trends Immunol 2020;41:692-705. [PMID: 32605801 DOI: 10.1016/j.it.2020.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
463 Assi HI, Kamphorst AO, Moukalled NM, Ramalingam SS. Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer 2018;124:248-61. [PMID: 29211297 DOI: 10.1002/cncr.31105] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
464 Subudhi SK, Zhou P, Yerian LM, Chin RK, Lo JC, Anders RA, Sun Y, Chen L, Wang Y, Alegre ML, Fu YX. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest 2004;113:694-700. [PMID: 14991067 DOI: 10.1172/JCI19210] [Cited by in Crossref: 105] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
465 Ankri C, Shamalov K, Horovitz-fried M, Mauer S, Cohen CJ. Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity. J I 2013;191:4121-9. [DOI: 10.4049/jimmunol.1203085] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 7.0] [Reference Citation Analysis]
466 Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8:e82870. [PMID: 24349382 DOI: 10.1371/journal.pone.0082870] [Cited by in Crossref: 175] [Cited by in F6Publishing: 182] [Article Influence: 19.4] [Reference Citation Analysis]
467 Chen T, Li Q, Liu Z, Chen Y, Feng F, Sun H. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy? Eur J Med Chem 2019;161:378-98. [PMID: 30384043 DOI: 10.1016/j.ejmech.2018.10.044] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
468 Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res 2017;23:3711-20. [PMID: 28167507 DOI: 10.1158/1078-0432.CCR-16-3215] [Cited by in Crossref: 354] [Cited by in F6Publishing: 217] [Article Influence: 70.8] [Reference Citation Analysis]
469 Dronca RS, Mansfield AS, Park SS, Dong H. BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. Immunotherapy 2016;8:1351-3. [PMID: 27784186 DOI: 10.2217/imt-2016-0100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
470 Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh MR, Momtazi-Borojeni AA, Chen S. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J Immunother Cancer 2021;9:e001698. [PMID: 33472857 DOI: 10.1136/jitc-2020-001698] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
471 Li X, Deng R, He W, Liu C, Wang M, Young J, Meng Z, Du C, Huang W, Chen L, Chen Y, Martin P, Forman S, Zeng D. Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease. J Immunol 2012;188:724-34. [PMID: 22156590 DOI: 10.4049/jimmunol.1102630] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
472 Mondello P, Cuzzocrea S, Navarra M, Mian M. Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. Oncotarget 2017;8:20394-409. [PMID: 28099912 DOI: 10.18632/oncotarget.14610] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
473 Tamura H. Immunopathogenesis and immunotherapy of multiple myeloma. Int J Hematol 2018;107:278-85. [PMID: 29368256 DOI: 10.1007/s12185-018-2405-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
474 Xu G, Sun L, Li Y, Xie F, Zhou X, Yang H, Du S, Xu H, Mao Y. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Front Oncol 2019;9:897. [PMID: 31620360 DOI: 10.3389/fonc.2019.00897] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
475 Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J, Wu C. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol. 2015;20:273-281. [PMID: 24804867 DOI: 10.1007/s10147-014-0701-7] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 8.6] [Reference Citation Analysis]
476 Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. [PMID: 28018338 DOI: 10.3389/fimmu.2016.00550] [Cited by in Crossref: 219] [Cited by in F6Publishing: 226] [Article Influence: 36.5] [Reference Citation Analysis]
477 Jin J, Zhao Q. Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration. Theranostics 2020;10:6231-44. [PMID: 32483450 DOI: 10.7150/thno.45219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
478 Xiao JX, Bai PS, Lai BC, Li L, Zhu J, Wang YL. B7 molecule mRNA expression in colorectal carcinoma. World J Gastroenterol 2005; 11(36): 5655-5658 [PMID: 16237760 DOI: 10.3748/wjg.v11.i36.5655] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
479 Li Z, Li B, Li L, Wang G, Li Y, Fu R, Ming Y, Ni R, Wang J, Ye G, Chen J. The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells. Onco Targets Ther 2020;13:12225-41. [PMID: 33273828 DOI: 10.2147/OTT.S281397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
480 Principe DR, DeCant B, Mascariñas E, Wayne EA, Diaz AM, Akagi N, Hwang R, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ. TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. Cancer Res 2016;76:2525-39. [PMID: 26980767 DOI: 10.1158/0008-5472.CAN-15-1293] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 14.3] [Reference Citation Analysis]
481 Yang S, Yao B, Wu L, Liu Y, Liu K, Xu P, Zheng Y, Deng Y, Zhai Z, Wu Y, Li N, Zhang D, Kang H, Dai Z. Ubiquitin-related molecular classification and risk stratification of hepatocellular carcinoma. Mol Ther Oncolytics 2021;21:207-19. [PMID: 34095460 DOI: 10.1016/j.omto.2021.04.003] [Reference Citation Analysis]
482 Mu L, Yu W, Su H, Lin Y, Sui W, Yu X, Qin C. Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer. Artif Cells Nanomed Biotechnol 2019;47:1036-42. [PMID: 30983436 DOI: 10.1080/21691401.2019.1573741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
483 Tseng YJ, Lee CH, Chen WY, Yang JL, Tzeng HT. Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade. J Invest Dermatol 2021:S0022-202X(21)01230-6. [PMID: 34000287 DOI: 10.1016/j.jid.2021.03.030] [Reference Citation Analysis]
484 Yang HY, Yang CC, Wu CY, Wang LJ, Lu KL. Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs. Int J Mol Sci 2019;20:E3162. [PMID: 31261684 DOI: 10.3390/ijms20133162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
485 Panetti C, Kao KC, Joller N. Dampening antiviral immunity can protect the host. FEBS J 2021. [PMID: 33570771 DOI: 10.1111/febs.15756] [Reference Citation Analysis]
486 Ren J, Xu M, Chen J, Ding J, Wang P, Huo L, Li F, Liu Z. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled αPD-L1 antibody. Theranostics 2021;11:304-15. [PMID: 33391476 DOI: 10.7150/thno.45540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
487 Zhuang H, Wang S, Chen B, Zhang Z, Ma Z, Li Z, Liu C, Zhou Z, Gong Y, Huang S, Hou B, Chen Y, Zhang C. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas. Front Immunol 2021;12:790661. [PMID: 34925373 DOI: 10.3389/fimmu.2021.790661] [Reference Citation Analysis]
488 Tamalunas A, Schulz GB, Rodler S, Apfelbeck M, Stief CG, Casuscelli J. [Systemic treatment of bladder cancer]. Urologe A 2021;60:247-58. [PMID: 33398384 DOI: 10.1007/s00120-020-01420-5] [Reference Citation Analysis]
489 Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2015;38:1-11. [PMID: 25415283 DOI: 10.1097/cji.0000000000000062] [Cited by in Crossref: 232] [Cited by in F6Publishing: 176] [Article Influence: 33.1] [Reference Citation Analysis]
490 Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 2008;21:39-55. [PMID: 18353142 DOI: 10.1111/j.1755-148X.2007.00427.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 82] [Article Influence: 9.9] [Reference Citation Analysis]
491 Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95-106. [PMID: 17251916 DOI: 10.1038/nrc2051] [Cited by in Crossref: 420] [Cited by in F6Publishing: 374] [Article Influence: 28.0] [Reference Citation Analysis]
492 Zhou B, Wang T, Lei L, Lu Y, Zhang L, Tang X, Qiu H, Sun A, Zhang X, Xu Y, Wu D. Prognostic values of increased B7 family proteins in haploidentical hematopoietic stem cell transplantation patients with aGVHD. Int J Hematol 2019;109:451-62. [PMID: 30725359 DOI: 10.1007/s12185-019-02605-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
493 Jarkowski A 3rd, Khushalani NI. BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog 2014;13:1. [PMID: 24737949 DOI: 10.4103/1477-3163.126759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
494 Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009;229:126-44. [PMID: 19426219 DOI: 10.1111/j.1600-065X.2009.00771.x] [Cited by in Crossref: 163] [Cited by in F6Publishing: 103] [Article Influence: 12.5] [Reference Citation Analysis]
495 Vazquez-Cintron EJ, Monu NR, Burns JC, Blum R, Chen G, Lopez P, Ma J, Radoja S, Frey AB. Protocadherin-18 is a novel differentiation marker and an inhibitory signaling receptor for CD8+ effector memory T cells. PLoS One 2012;7:e36101. [PMID: 22567129 DOI: 10.1371/journal.pone.0036101] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
496 Sun H, Liu SY, Zhou JY, Xu JT, Zhang HK, Yan HH, Huan JJ, Dai PP, Xu CR, Su J, Guan YF, Yi X, Yu RS, Zhong WZ, Wu YL. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. EBioMedicine 2020;60:102990. [PMID: 32927274 DOI: 10.1016/j.ebiom.2020.102990] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
497 Xiang X, Yu PC, Long D, Liao XL, Zhang S, You XM, Zhong JH, Li LQ. Prognostic value of PD -L1 expression in patients with primary solid tumors. Oncotarget 2018;9:5058-72. [PMID: 29435162 DOI: 10.18632/oncotarget.23580] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
498 Hotta K, Fujimoto N. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma. J Immunother Cancer 2020;8:e000461. [PMID: 32098830 DOI: 10.1136/jitc-2019-000461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
499 Shah DJ, Dronca RS. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc 2014;89:504-19. [PMID: 24684873 DOI: 10.1016/j.mayocp.2014.02.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
500 Lo CH, Kwon S, Wang L, Polychronidis G, Knudsen MD, Zhong R, Cao Y, Wu K, Ogino S, Giovannucci EL, Chan AT, Song M. Periodontal disease, tooth loss, and risk of oesophageal and gastric adenocarcinoma: a prospective study. Gut 2021;70:620-1. [PMID: 32690603 DOI: 10.1136/gutjnl-2020-321949] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
501 Torphy RJ, Schulick RD, Zhu Y. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. Int J Mol Sci 2017;18:E2642. [PMID: 29211042 DOI: 10.3390/ijms18122642] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
502 Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. Br J Cancer 2020;122:306-14. [PMID: 31708575 DOI: 10.1038/s41416-019-0602-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
503 Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Curr Hematol Malig Rep 2020;15:372-81. [PMID: 32394185 DOI: 10.1007/s11899-020-00589-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
504 Lan Q, Ji C, Yao Y. [Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC]. Zhongguo Fei Ai Za Zhi 2019;22:512-9. [PMID: 31451142 DOI: 10.3779/j.issn.1009-3419.2019.08.06] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
505 Sun DW, An L, Huang HY, Sun XD, Lv GY. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true? Clin Transl Oncol 2021;23:82-91. [PMID: 32462395 DOI: 10.1007/s12094-020-02390-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
506 Nakazawa N, Yokobori T, Kaira K, Turtoi A, Baatar S, Gombodorj N, Handa T, Tsukagoshi M, Ubukata Y, Kimura A, Kogure N, Ogata K, Maeno T, Sohda M, Yajima T, Shimizu K, Mogi A, Kuwano H, Saeki H, Shirabe K. High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors. Ann Surg Oncol 2020;27:933-42. [PMID: 31571056 DOI: 10.1245/s10434-019-07878-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
507 Al Diffalha S, Sexton KC, Watson PH, Grizzle WE. The Importance of Human Tissue Bioresources in Advancing Biomedical Research. Biopreserv Biobank 2019;17:209-12. [PMID: 31188626 DOI: 10.1089/bio.2019.0039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
508 Sun NY, Chen YL, Lin HW, Chiang YC, Chang CF, Tai YJ, Chen CA, Sun WZ, Chien CL, Cheng WF. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Cancer Lett 2019;444:20-34. [PMID: 30543813 DOI: 10.1016/j.canlet.2018.11.039] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
509 Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 2004;101:17174-17179. [PMID: 15569934 DOI: 10.1073/pnas.0406351101] [Cited by in Crossref: 566] [Cited by in F6Publishing: 527] [Article Influence: 31.4] [Reference Citation Analysis]
510 Qiao XW, Jiang J, Pang X, Huang MC, Tang YJ, Liang XH, Tang YL. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. Front Immunol 2020;11:1721. [PMID: 33072064 DOI: 10.3389/fimmu.2020.01721] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
511 Suresh S, Chen B, Zhu J, Golden RJ, Lu C, Evers BM, Novaresi N, Smith B, Zhan X, Schmid V, Jun S, Karacz CM, Peyton M, Zhong L, Wen Z, Sathe AA, Xing C, Behrens C, Wistuba II, Xiao G, Xie Y, Fu YX, Minna JD, Mendell JT, O'Donnell KA. eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nat Cancer 2020;1:533-45. [PMID: 32984844 DOI: 10.1038/s43018-020-0056-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
512 Guo W, Tan W, Liu S, Huang X, Lin J, Liang R, Su L, Su Q, Wang C. MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. Tumour Biol 2015;36:9049-57. [PMID: 26084609 DOI: 10.1007/s13277-015-3644-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
513 Hornig N, Reinhardt K, Kermer V, Kontermann RE, Müller D. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. Cancer Immunol Immunother 2013;62:1369-80. [PMID: 23715927 DOI: 10.1007/s00262-013-1441-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
514 Wei W, Xu B, Wang Y, Wu C, Jiang J, Wu C. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis. Medicine (Baltimore) 2018;97:e9617. [PMID: 29504990 DOI: 10.1097/MD.0000000000009617] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
515 Pezeshki PS, Eskian M, Hamblin MR, Rezaei N. Immune checkpoint inhibition in classical hodgkin lymphoma. Expert Rev Anticancer Ther 2021;21:1003-16. [PMID: 33857395 DOI: 10.1080/14737140.2021.1918548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
516 Lee JR, Bechstein DJ, Ooi CC, Patel A, Gaster RS, Ng E, Gonzalez LC, Wang SX. Magneto-nanosensor platform for probing low-affinity protein-protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction. Nat Commun 2016;7:12220. [PMID: 27447090 DOI: 10.1038/ncomms12220] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
517 Hendriks D, Choi G, de Bruyn M, Wiersma VR, Bremer E. Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches. Int Rev Cell Mol Biol 2017;331:289-383. [PMID: 28325214 DOI: 10.1016/bs.ircmb.2016.10.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
518 Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell. 2019;76:359-370. [PMID: 31668929 DOI: 10.1016/j.molcel.2019.09.030] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 25.0] [Reference Citation Analysis]
519 Ring A, Müller AMS. [Chemotherapy-Free Treatment of Hematological Neoplasias: Dream or Reality?]. Praxis (Bern 1994) 2019;108:411-8. [PMID: 31039712 DOI: 10.1024/1661-8157/a003230] [Reference Citation Analysis]
520 Singh PP, Sharma PK, Krishnan G, Lockhart AC. Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf). 2015;3:289-297. [PMID: 26510455 DOI: 10.1093/gastro/gov053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
521 Vilgelm AE, Johnson DB, Richmond A. Combinatorial approach to cancer immunotherapy: strength in numbers. J Leukoc Biol 2016;100:275-90. [PMID: 27256570 DOI: 10.1189/jlb.5RI0116-013RR] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
522 Li C, Zhu B, Son YM, Wang Z, Jiang L, Xiang M, Ye Z, Beckermann KE, Wu Y, Jenkins JW, Siska PJ, Vincent BG, Prakash YS, Peikert T, Edelson BT, Taneja R, Kaplan MH, Rathmell JC, Dong H, Hitosugi T, Sun J. The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality. Immunity 2019;51:491-507.e7. [PMID: 31533057 DOI: 10.1016/j.immuni.2019.08.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 18.7] [Reference Citation Analysis]
523 Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013;139:667-76. [PMID: 23756627 DOI: 10.1007/s10549-013-2581-3] [Cited by in Crossref: 191] [Cited by in F6Publishing: 187] [Article Influence: 21.2] [Reference Citation Analysis]
524 Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, Zhu L, Zhu J, Joshi M, Belani CP. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget 2016;7:56233-40. [PMID: 27191652 DOI: 10.18632/oncotarget.9316] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
525 Hsieh TC, Wu JM. Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage ("SEE") Signal to Facilitate the Elimination of "Cold, Non-Responsive" Low PD-L1-Expressing Tumors by PD-L1 Blockade. Int J Mol Sci 2019;20:E5969. [PMID: 31783532 DOI: 10.3390/ijms20235969] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
526 Loose D, Van de Wiele C. The immune system and cancer. Cancer Biother Radiopharm. 2009;24:369-376. [PMID: 19538060 DOI: 10.1089/cbr.2008.0593] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
527 Niccolai E, Ricci F, Russo E, Nannini G, Emmi G, Taddei A, Ringressi MN, Melli F, Miloeva M, Cianchi F, Bechi P, Prisco D, Amedei A. The Different Functional Distribution of "Not Effector" T Cells (Treg/Tnull) in Colorectal Cancer. Front Immunol. 2017;8:1900. [PMID: 29375559 DOI: 10.3389/fimmu.2017.01900] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
528 Sträter J, Möller P. CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts. Virchows Arch 2003;442:218-25. [DOI: 10.1007/s00428-003-0760-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
529 Palsson-McDermott EM, Dyck L, Zasłona Z, Menon D, McGettrick AF, Mills KHG, O'Neill LA. Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors. Front Immunol 2017;8:1300. [PMID: 29081778 DOI: 10.3389/fimmu.2017.01300] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 13.8] [Reference Citation Analysis]
530 Shen H, Sun T, Hoang HH, Burchfield JS, Hamilton GF, Mittendorf EA, Ferrari M. Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Semin Immunol 2017;34:114-22. [PMID: 28947107 DOI: 10.1016/j.smim.2017.09.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
531 Wang M, Wang J, Wang R, Jiao S, Wang S, Zhang J, Zhang M. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation. Commun Biol 2019;2:392. [PMID: 31667366 DOI: 10.1038/s42003-019-0642-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
532 Smith P, Walsh CM, Mangan NE, Fallon RE, Sayers JR, McKenzie AN, Fallon PG. Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages. J Immunol 2004;173:1240-8. [PMID: 15240716 DOI: 10.4049/jimmunol.173.2.1240] [Cited by in Crossref: 149] [Cited by in F6Publishing: 146] [Article Influence: 8.3] [Reference Citation Analysis]
533 Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res 2017;23:4270-9. [PMID: 28223273 DOI: 10.1158/1078-0432.CCR-16-3146] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 15.4] [Reference Citation Analysis]
534 Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World J Surg. 2010;34:1059-1065. [PMID: 20145927 DOI: 10.1007/s00268-010-0448-x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 6.4] [Reference Citation Analysis]
535 Strome SE, Chen L. Costimulation-based immunotherapy for head and neck cancer. Curr Treat Options Oncol 2004;5:27-33. [PMID: 14697154 DOI: 10.1007/s11864-004-0003-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
536 Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K, Chen L. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol. 2003;171:4650-4654. [PMID: 14568939 DOI: 10.4049/jimmunol.171.9.4650] [Cited by in Crossref: 177] [Cited by in F6Publishing: 162] [Article Influence: 9.8] [Reference Citation Analysis]
537 Pan X, Zhong A, Xing Y, Shi M, Qian B, Zhou T, Chen Y, Zhang X. Increased soluble and membrane-bound PD-L1 contributes to immune regulation and disease progression in patients with tuberculous pleural effusion. Exp Ther Med 2016;12:2161-8. [PMID: 27698705 DOI: 10.3892/etm.2016.3611] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
538 Tung JN, Lin PL, Wang YC, Wu DW, Chen CY, Lee H. PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression. Oncotarget 2018;9:4637-46. [PMID: 29435131 DOI: 10.18632/oncotarget.23161] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
539 Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 2018;6:39. [PMID: 29769148 DOI: 10.1186/s40425-018-0349-3] [Cited by in Crossref: 139] [Cited by in F6Publishing: 138] [Article Influence: 34.8] [Reference Citation Analysis]
540 Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X, Deng L, Wang Y, Zhang X, Jiang T, Lu X. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. J Immunother 2016;39:171-80. [PMID: 27070448 DOI: 10.1097/CJI.0000000000000122] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
541 Maine CJ, Aziz NH, Chatterjee J, Hayford C, Brewig N, Whilding L, George AJ, Ghaem-Maghami S. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother 2014;63:215-24. [PMID: 24297569 DOI: 10.1007/s00262-013-1503-x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 7.7] [Reference Citation Analysis]
542 Li M, Zhou ZH, Sun XH, Zhang X, Zhu XJ, Jin SG, Gao YT, Jiang Y, Gao YQ. Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence. Lab Invest 2016;96:1156-64. [PMID: 27617403 DOI: 10.1038/labinvest.2016.96] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
543 Matsumoto K, Inoue H, Nakano T, Tsuda M, Yoshiura Y, Fukuyama S, Tsushima F, Hoshino T, Aizawa H, Akiba H, Pardoll D, Hara N, Yagita H, Azuma M, Nakanishi Y. B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. J Immunol 2004;172:2530-41. [PMID: 14764726 DOI: 10.4049/jimmunol.172.4.2530] [Cited by in Crossref: 99] [Cited by in F6Publishing: 98] [Article Influence: 5.5] [Reference Citation Analysis]
544 Yang A, Li MY, Zhang ZH, Wang JY, Xing Y, Ri M, Jin CH, Xu GH, Piao LX, Jin HL, Zuo HX, Ma J, Jin X. Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity. J Ethnopharmacol 2021;273:113598. [PMID: 33220359 DOI: 10.1016/j.jep.2020.113598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
545 Marrocco I, Romaniello D, Yarden Y. Cancer Immunotherapy: The Dawn of Antibody Cocktails. Methods Mol Biol 2019;1904:11-51. [PMID: 30539465 DOI: 10.1007/978-1-4939-8958-4_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
546 Wang GZ, Zhang L, Zhao XC, Gao SH, Qu LW, Yu H, Fang WF, Zhou YC, Liang F, Zhang C, Huang YC, Liu Z, Fu YX, Zhou GB. The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nat Commun 2019;10:1125. [PMID: 30850589 DOI: 10.1038/s41467-019-08887-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 14.3] [Reference Citation Analysis]
547 Wang HC, Hung WC, Chen LT, Pan MR. From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. Int J Mol Sci 2018;19:E3584. [PMID: 30428588 DOI: 10.3390/ijms19113584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
548 Matsuda K, Miyoshi H, Hiraoka K, Hamada T, Yoshida S, Ishibashi Y, Haraguchi T, Shiba N, Ohshima K. Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis. Clin Exp Med 2018;18:487-94. [DOI: 10.1007/s10238-018-0515-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
549 Tunger A, Kießler M, Wehner R, Temme A, Meier F, Bachmann M, Schmitz M. Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines 2018;6:E26. [PMID: 29494517 DOI: 10.3390/biomedicines6010026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
550 Acúrcio RC, Scomparin A, Conniot J, Salvador JAR, Satchi-fainaro R, Florindo HF, Guedes RC. Structure–Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy. J Med Chem 2018;61:10957-75. [DOI: 10.1021/acs.jmedchem.8b00541] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
551 Righi I, Vaira V, Morlacchi LC, Croci GA, Rossetti V, Blasi F, Ferrero S, Nosotti M, Rosso L, Clerici M. Immune Checkpoints Expression in Chronic Lung Allograft Rejection. Front Immunol 2021;12:714132. [PMID: 34489963 DOI: 10.3389/fimmu.2021.714132] [Reference Citation Analysis]
552 Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, Blink S, Wang Y, Wang J, Liu X, Mink K, Degrandi D, Pfeffer K, Fu YX. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest 2005;115:711-7. [PMID: 15696194 DOI: 10.1172/JCI22982] [Cited by in Crossref: 6] [Cited by in F6Publishing: 78] [Article Influence: 0.4] [Reference Citation Analysis]
553 Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Korman AJ, Lowy I. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 2013;8:e63818. [PMID: 23717490 DOI: 10.1371/journal.pone.0063818] [Cited by in Crossref: 173] [Cited by in F6Publishing: 167] [Article Influence: 19.2] [Reference Citation Analysis]
554 Kim HM, Lee J, Koo JS. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. BMC Cancer 2017;17:690. [PMID: 29041905 DOI: 10.1186/s12885-017-3670-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
555 Afreen S, Dermime S. The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematology/Oncology and Stem Cell Therapy 2014;7:1-17. [DOI: 10.1016/j.hemonc.2013.09.005] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 8.0] [Reference Citation Analysis]
556 Chiossone L, Vienne M, Kerdiles YM, Vivier E. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more. Seminars in Immunology 2017;31:55-63. [DOI: 10.1016/j.smim.2017.08.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 13.8] [Reference Citation Analysis]
557 Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreibelt G, de Boer A, Van Herpen CM, Kaanders JH. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011;121:3100-3108. [PMID: 21765211 DOI: 10.1172/jci43656] [Cited by in Crossref: 177] [Cited by in F6Publishing: 105] [Article Influence: 16.1] [Reference Citation Analysis]
558 Mentlik James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 2013;4:481. [PMID: 24391651 DOI: 10.3389/fimmu.2013.00481] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
559 Ishikawa E, Kato S, Shimada K, Tanaka T, Suzuki Y, Satou A, Kohno K, Sakakibara A, Yamamura T, Nakamura M, Miyahara R, Goto H, Nakamura S, Hirooka Y. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells. Cancer Med 2018;7:6051-63. [PMID: 30449068 DOI: 10.1002/cam4.1875] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
560 Xie J, Fu L, Jin L. Immunotherapy of gastric cancer: Past, future perspective and challenges. Pathol Res Pract 2021;218:153322. [PMID: 33422778 DOI: 10.1016/j.prp.2020.153322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
561 Gong AY, Zhou R, Hu G, Liu J, Sosnowska D, Drescher KM, Dong H, Chen XM. Cryptosporidium parvum induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513. J Infect Dis 2010;201:160-9. [PMID: 19916867 DOI: 10.1086/648589] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
562 Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111-122. [PMID: 17629517 DOI: 10.1016/j.immuni.2007.05.016] [Cited by in Crossref: 1038] [Cited by in F6Publishing: 1031] [Article Influence: 69.2] [Reference Citation Analysis]
563 Galvin KC, Conroy MJ, Doyle SL, Dunne MR, Fahey R, Foley E, O'Sullivan KE, Doherty DG, Geoghegan JG, Ravi N, O'Farrelly C, Reynolds JV, Lysaght J. Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma. Cancer Lett 2018;418:230-8. [PMID: 29339209 DOI: 10.1016/j.canlet.2018.01.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
564 Feld E, Mitchell TC. Immunotherapy in melanoma. Immunotherapy 2018;10:987-98. [PMID: 30149766 DOI: 10.2217/imt-2017-0143] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
565 Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, Nishikawa H. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 2020;21:1346-58. [DOI: 10.1038/s41590-020-0769-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 28.5] [Reference Citation Analysis]
566 Dickinson SE, Khawam M, Kirschnerova V, Vaishampayan P, Centuori SM, Saboda K, Calvert VS, Petricoin EF 3rd, Curiel-Lewandrowski C. Increased PD-L1 Expression in Human Skin Acutely and Chronically Exposed to UV Irradiation. Photochem Photobiol 2021;97:778-84. [PMID: 33615483 DOI: 10.1111/php.13406] [Reference Citation Analysis]
567 Hazama D, Yin Y, Murata Y, Matsuda M, Okamoto T, Tanaka D, Terasaka N, Zhao J, Sakamoto M, Kakuchi Y, Saito Y, Kotani T, Nishimura Y, Nakagawa A, Suga H, Matozaki T. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy. Cell Chem Biol 2020;27:1181-1191.e7. [PMID: 32640189 DOI: 10.1016/j.chembiol.2020.06.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
568 Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020;20:651-68. [PMID: 32433532 DOI: 10.1038/s41577-020-0306-5] [Cited by in Crossref: 280] [Cited by in F6Publishing: 291] [Article Influence: 140.0] [Reference Citation Analysis]
569 Abbas M, Steffens S, Bellut M, Eggers H, Großhennig A, Becker JU, Wegener G, Schrader AJ, Grünwald V, Ivanyi P. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Med Oncol 2016;33:80. [PMID: 27317388 DOI: 10.1007/s12032-016-0794-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
570 Gouw LG, Jones KB, Sharma S, Randall RL. Sarcoma immunotherapy. Cancers (Basel) 2011;3:4139-50. [PMID: 24213130 DOI: 10.3390/cancers3044139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
571 Polioudaki H, Mala A, Gkimprixi E, Papadaki MA, Chantziou A, Tzardi M, Mavroudis D, Agelaki S, Theodoropoulos PA. Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome. Cancers (Basel) 2020;12:E3735. [PMID: 33322610 DOI: 10.3390/cancers12123735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
572 Tian W, Sun Y, Cheng Y, Ma X, Du W, Shi W, Guo Q. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1. Thorac Cancer 2021;12:2551-63. [PMID: 34469060 DOI: 10.1111/1759-7714.14136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
573 Schlößer HA, Theurich S, Shimabukuro-Vornhagen A, Holtick U, Stippel DL, von Bergwelt-Baildon M. Overcoming tumor-mediated immunosuppression. Immunotherapy 2014;6:973-88. [PMID: 25341119 DOI: 10.2217/imt.14.58] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
574 Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol. 2014;4:325. [PMID: 25506582 DOI: 10.3389/fonc.2014.00325] [Cited by in Crossref: 139] [Cited by in F6Publishing: 138] [Article Influence: 17.4] [Reference Citation Analysis]
575 Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist. 2008;13 Suppl 4:16-25. [PMID: 19001147 DOI: 10.1634/theoncologist.13-s4-16] [Cited by in Crossref: 66] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
576 Skafi N, Fayyad-Kazan M, Badran B. Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression. Gene 2020;754:144888. [PMID: 32544493 DOI: 10.1016/j.gene.2020.144888] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
577 Eymerit-Morin C, Ilenko A, Gaillard T, Varinot J, Compérat E, Bendifallah S, Darai E. PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases. Eur J Histochem 2021;65. [PMID: 33728864 DOI: 10.4081/ejh.2021.3185] [Reference Citation Analysis]
578 Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, Deguchi T, Kato Y, Yamamoto S, Yamamoto K, Toda M, Nakajima C, Suzuki Y, Murata S, Ohashi K. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol 2021;5:10. [PMID: 33580183 DOI: 10.1038/s41698-021-00147-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
579 Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, Cabiddu M, Ghilardi M, Borgonovo K, Parati MC, Tomasello G, Barni S, Berruti A, Brighenti M. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Journal of Immunotherapy 2020;43:1-7. [DOI: 10.1097/cji.0000000000000300] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
580 Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer 2018;143:3019-26. [PMID: 29923182 DOI: 10.1002/ijc.31624] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
581 Willemsen M, Melief CJM, Bekkenk MW, Luiten RM. Targeting the PD-1/PD-L1 Axis in Human Vitiligo. Front Immunol 2020;11:579022. [PMID: 33240267 DOI: 10.3389/fimmu.2020.579022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
582 Hossain MS, Kunter GM, El-Najjar VF, Jaye DL, Al-Kadhimi Z, Taofeek OK, Li JM, Waller EK. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients. PLoS One 2017;12:e0184254. [PMID: 28953925 DOI: 10.1371/journal.pone.0184254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
583 Gao L, Chen Y. Autophagy controls programmed death-ligand 1 expression on cancer cells (Review). Biomed Rep 2021;15:84. [PMID: 34512972 DOI: 10.3892/br.2021.1460] [Reference Citation Analysis]
584 Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 2009;69:8067-75. [PMID: 19826049 DOI: 10.1158/0008-5472.CAN-09-0901] [Cited by in Crossref: 215] [Cited by in F6Publishing: 141] [Article Influence: 16.5] [Reference Citation Analysis]
585 Gandhi L, Vansteenkiste JF, Shepherd FA. Immunotherapy and Lung Cancer. IASLC Thoracic Oncology. Elsevier; 2018. pp. 501-511.e3. [DOI: 10.1016/b978-0-323-52357-8.00050-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
586 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264. [PMID: 22437870 DOI: 10.1038/nrc3239] [Cited by in Crossref: 6827] [Cited by in F6Publishing: 6453] [Article Influence: 682.7] [Reference Citation Analysis]
587 Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008;111:3635-43. [PMID: 18223165 DOI: 10.1182/blood-2007-11-123141] [Cited by in Crossref: 302] [Cited by in F6Publishing: 286] [Article Influence: 21.6] [Reference Citation Analysis]
588 Chang WA, Tsai MJ, Hung JY, Wu KL, Tsai YM, Huang YC, Chang CY, Tsai PH, Hsu YL. miR-150-5p-Containing Extracellular Vesicles Are a New Immunoregulator That Favor the Progression of Lung Cancer in Hypoxic Microenvironments by Altering the Phenotype of NK Cells. Cancers (Basel) 2021;13:6252. [PMID: 34944871 DOI: 10.3390/cancers13246252] [Reference Citation Analysis]
589 Isshiki T, Isobe K, Tochigi N, Sunakawa M, Nakamura Y, Shibuya K, Sakamoto S, Takai Y, Homma S. Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression. Case Rep Oncol. 2018;11:688-692. [PMID: 30483099 DOI: 10.1159/000493187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
590 He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A, Zhou C, Hirsch FR. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci. 2016;107:1193-1197. [PMID: 27297395 DOI: 10.1111/cas.12986] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 14.2] [Reference Citation Analysis]
591 Smith J, Robida MD, Acosta K, Vennapusa B, Mistry A, Martin G, Yates A, Hnatyszyn HJ. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N. Diagn Pathol. 2016;11:44. [PMID: 27189072 DOI: 10.1186/s13000-016-0494-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
592 Kim JH, Kim SY, Shin EY, Jung JH, Choi HJ, Jun KH. Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer. Oncol Lett 2019;18:2661-9. [PMID: 31452748 DOI: 10.3892/ol.2019.10594] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
593 Kushchayev SV, Kushchayeva YS, Wiener PC, Scheck AC, Badie B, Preul MC. Monocyte-derived cells of the brain and malignant gliomas: the double face of Janus. World Neurosurg 2014;82:1171-86. [PMID: 23178919 DOI: 10.1016/j.wneu.2012.11.059] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
594 Nowicki TS, Anderson JL, Federman N. Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. Pediatr Res 2016;79:371-7. [PMID: 26595537 DOI: 10.1038/pr.2015.246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
595 Polónia A, Pinto R, Cameselle-Teijeiro JF, Schmitt FC, Paredes J. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. J Clin Pathol 2017;70:860-7. [PMID: 28373294 DOI: 10.1136/jclinpath-2016-203990] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
596 Bardhan K, Aksoylar HI, Le Bourgeois T, Strauss L, Weaver JD, Delcuze B, Charest A, Patsoukis N, Boussiotis VA. Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells. Sci Rep 2019;9:17252. [PMID: 31754127 DOI: 10.1038/s41598-019-53463-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
597 Wang J, Song YX, Ma B, Wang JJ, Sun JX, Chen XW, Zhao JH, Yang YC, Wang ZN. Regulatory Roles of Non-Coding RNAs in Colorectal Cancer. Int J Mol Sci. 2015;16:19886-19919. [PMID: 26307974 DOI: 10.3390/ijms160819886] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
598 Ueda K, Suekane S, Kurose H, Chikui K, Nakiri M, Nishihara K, Matsuo M, Kawahara A, Yano H, Igawa T. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. Urol Oncol 2018;36:499.e9-499.e16. [PMID: 30131293 DOI: 10.1016/j.urolonc.2018.07.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
599 Wu S, Calero-Pérez P, Villamañan L, Arias-Ramos N, Pumarola M, Ortega-Martorell S, Julià-Sapé M, Arús C, Candiota AP. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images. NMR Biomed 2020;33:e4229. [PMID: 31926117 DOI: 10.1002/nbm.4229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
600 He X, Abrams SI, Lovell JF. Peptide Delivery Systems for Cancer Vaccines. Adv Therap 2018;1:1800060. [DOI: 10.1002/adtp.201800060] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
601 Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012;60:199-215. [PMID: 22212087 DOI: 10.1111/j.1365-2559.2011.04033.x] [Cited by in Crossref: 350] [Cited by in F6Publishing: 329] [Article Influence: 35.0] [Reference Citation Analysis]
602 Ganesan A, Ahmed M, Okoye I, Arutyunova E, Babu D, Turnbull WL, Kundu JK, Shields J, Agopsowicz KC, Xu L, Tabana Y, Srivastava N, Zhang G, Moon TC, Belovodskiy A, Hena M, Kandadai AS, Hosseini SN, Hitt M, Walker J, Smylie M, West FG, Siraki AG, Lemieux MJ, Elahi S, Nieman JA, Tyrrell DL, Houghton M, Barakat K. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. Sci Rep 2019;9:12392. [PMID: 31455818 DOI: 10.1038/s41598-019-48826-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
603 Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51-81. [PMID: 16730261 DOI: 10.1016/s0065-2776(06)90002-9] [Cited by in Crossref: 441] [Cited by in F6Publishing: 242] [Article Influence: 33.9] [Reference Citation Analysis]
604 Shelby A, Pendleton C, Thayer E, Johnson GK, Xie XJ, Brogden KA. PD-L1 correlates with chemokines and cytokines in gingival crevicular fluid from healthy and diseased sites in subjects with periodontitis. BMC Res Notes 2020;13:532. [PMID: 33187554 DOI: 10.1186/s13104-020-05376-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
605 Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, Marone G, Tocchetti CG. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2017;2:e000247. [PMID: 29104763 DOI: 10.1136/esmoopen-2017-000247] [Cited by in Crossref: 98] [Cited by in F6Publishing: 91] [Article Influence: 19.6] [Reference Citation Analysis]
606 Srivastava V, Akshay BR, Kumari S, Meena RN, Khanna R. Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting. J Family Med Prim Care 2020;9:4086-91. [PMID: 33110814 DOI: 10.4103/jfmpc.jfmpc_493_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
607 Ruan Q, Wang H, Burke LJ, Bridle KR, Li X, Zhao CX, Crawford DHG, Roberts MS, Liang X. Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma. Int J Cancer 2020;147:1519-27. [PMID: 32010970 DOI: 10.1002/ijc.32899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
608 Pelaez-Prestel HF, Sanchez-Trincado JL, Lafuente EM, Reche PA. Immune Tolerance in the Oral Mucosa. Int J Mol Sci 2021;22:12149. [PMID: 34830032 DOI: 10.3390/ijms222212149] [Reference Citation Analysis]
609 Zhou H, Fu X, Li Q, Niu T. Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails. Front Pharmacol 2019;10:387. [PMID: 31118893 DOI: 10.3389/fphar.2019.00387] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
610 Mletzko S, Pinato DJ, Robey RC, Dalla Pria A, Benson P, Imami N, Bower M. Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study. Oncoimmunology 2017;6:e1304337. [PMID: 28919987 DOI: 10.1080/2162402X.2017.1304337] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
611 Drijvers JM, Sharpe AH, Haigis MC. The effects of age and systemic metabolism on anti-tumor T cell responses. Elife 2020;9:e62420. [PMID: 33170123 DOI: 10.7554/eLife.62420] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
612 Wang Y, Li Z, Zhang Z, Chen X. Identification ACTA2 and KDR as key proteins for prognosis of PD-1/PD-L1 blockade therapy in melanoma. Animal Model Exp Med 2021;4:138-50. [PMID: 34179721 DOI: 10.1002/ame2.12154] [Reference Citation Analysis]
613 David P, Drabczyk-Pluta M, Pastille E, Knuschke T, Werner T, Honke N, Megger DA, Akhmetzyanova I, Shaabani N, Eyking-Singer A, Cario E, Kershaw O, Gruber AD, Tenbusch M, Dietze KK, Trilling M, Liu J, Schadendorf D, Streeck H, Lang KS, Xie Y, Zimmer L, Sitek B, Paschen A, Westendorf AM, Dittmer U, Zelinskyy G. Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology. PLoS Pathog 2020;16:e1008340. [PMID: 32226027 DOI: 10.1371/journal.ppat.1008340] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
614 Ho CM, Chen HL, Hu RH, Lee PH. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective. Ther Adv Med Oncol 2019;11:1758835919843463. [PMID: 31065295 DOI: 10.1177/1758835919843463] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
615 Wang B, Tian T, Kalland K, Ke X, Qu Y. Targeting Wnt/β-Catenin Signaling for Cancer Immunotherapy. Trends in Pharmacological Sciences 2018;39:648-58. [DOI: 10.1016/j.tips.2018.03.008] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 21.0] [Reference Citation Analysis]
616 Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 2018;8:1156-75. [PMID: 30012853 DOI: 10.1158/2159-8290.CD-17-1033] [Cited by in Crossref: 150] [Cited by in F6Publishing: 108] [Article Influence: 37.5] [Reference Citation Analysis]
617 Ring EK, Markert JM, Gillespie GY, Friedman GK. Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. Clin Cancer Res 2017;23:342-50. [PMID: 27836863 DOI: 10.1158/1078-0432.CCR-16-1829] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
618 Tang F, Zhang P, Ye P, Lazarski CA, Wu Q, Bergin IL, Bender TP, Hall MN, Cui Y, Zhang L, Jiang T, Liu Y, Zheng P. A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice. Elife 2017;6:e32497. [PMID: 29206103 DOI: 10.7554/eLife.32497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
619 Pilipow K, Darwich A, Losurdo A. T-cell-based breast cancer immunotherapy. Semin Cancer Biol 2021;72:90-101. [PMID: 32492452 DOI: 10.1016/j.semcancer.2020.05.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
620 Egan K, Crowley D, Smyth P, O'Toole S, Spillane C, Martin C, Gallagher M, Canney A, Norris L, Conlon N, McEvoy L, Ffrench B, Stordal B, Keegan H, Finn S, McEneaney V, Laios A, Ducrée J, Dunne E, Smith L, Berndt M, Sheils O, Kenny D, O'Leary J. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One 2011;6:e26125. [PMID: 22022533 DOI: 10.1371/journal.pone.0026125] [Cited by in Crossref: 103] [Cited by in F6Publishing: 105] [Article Influence: 9.4] [Reference Citation Analysis]
621 Beier KT. The Serendipity of Viral Trans-Neuronal Specificity: More Than Meets the Eye. Front Cell Neurosci 2021;15:720807. [PMID: 34671244 DOI: 10.3389/fncel.2021.720807] [Reference Citation Analysis]
622 Zarrabi K, Wu S. Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma. Curr Oncol Rep 2018;20:41. [PMID: 29611002 DOI: 10.1007/s11912-018-0684-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
623 Waldron JS, Yang I, Han S, Tihan T, Sughrue ME, Mills SA, Pieper RO, Parsa AT. Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. J Clin Neurosci 2010;17:1543-7. [PMID: 20822910 DOI: 10.1016/j.jocn.2010.04.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
624 Rausch MP, Hastings KT; Surface Oncology, 50 Hampshire Street, 8th Floor, Cambridge, MA 02139, USA, Department of Basic Medical Sciences, The University of Arizona, College of Medicine–Phoenix, AZ, USA. Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application. In: Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy. Codon Publications; 2017. pp. 121-42. [DOI: 10.15586/codon.cutaneousmelanoma.2017.ch9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
625 Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Paireder M, Kristo I, Kazakov D, Michal M, Cozzio A, Hoetzenecker W, Schatton T, Asari R, Preusser M, Guenova E, Schoppmann SF. Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. Ann Surg Oncol 2017;24:2698-706. [PMID: 28429196 DOI: 10.1245/s10434-017-5858-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
626 Yang J, Hu M, Bai X, Ding X, Xie L, Ma J, Fan B, Yu J. Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study. Medicine (Baltimore) 2019;98:e17231. [PMID: 31574833 DOI: 10.1097/MD.0000000000017231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
627 Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer 2018;6:140. [PMID: 30514385 DOI: 10.1186/s40425-018-0458-z] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 19.3] [Reference Citation Analysis]
628 Zhang J, Yi J, Zhou P. Development of bispecific antibodies in China: overview and prospects. Antib Ther 2020;3:126-45. [PMID: 33928227 DOI: 10.1093/abt/tbaa011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
629 Wang L. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study. J Ovarian Res 2019;12:37. [PMID: 31039792 DOI: 10.1186/s13048-019-0512-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
630 Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, Kondo T, Ohmori K, Kurata M, Hayashi T, Uchiyama T. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008;111:3220-4. [PMID: 18203952 DOI: 10.1182/blood-2007-05-085159] [Cited by in Crossref: 262] [Cited by in F6Publishing: 252] [Article Influence: 18.7] [Reference Citation Analysis]
631 Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54. [PMID: 22658127 DOI: 10.1056/NEJMoa1200690] [Cited by in Crossref: 7634] [Cited by in F6Publishing: 4584] [Article Influence: 763.4] [Reference Citation Analysis]
632 Long L, Chen M, Yuan Y, Ming AL, Guo W, Wu K, Chen H. High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma. J Cancer 2020;11:4442-52. [PMID: 32489463 DOI: 10.7150/jca.42610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
633 Rezasoltani S, Yadegar A, Asadzadeh Aghdaei H, Reza Zali M. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors. Cancer Med 2021;10:1141-54. [PMID: 33369247 DOI: 10.1002/cam4.3694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
634 Parney IF. Basic Concepts in Glioma Immunology. In: Yamanaka R, editor. Glioma. New York: Springer; 2012. pp. 42-52. [DOI: 10.1007/978-1-4614-3146-6_4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
635 Liu Z, Sun L, Cai L, Guo M, Xu G, Liu S, Zheng G, Wang Q, Lian X, Feng F, Zhang H. Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients. Postgrad Med J 2021:postgradmedj-2021-140029. [PMID: 34253568 DOI: 10.1136/postgradmedj-2021-140029] [Reference Citation Analysis]
636 Han X, Wang L, Li T, Zhang J, Zhang D, Li J, Xia Y, Liu Y, Tan W. Beyond Blocking: Engineering RNAi-Mediated Targeted Immune Checkpoint Nanoblocker Enables T-Cell-Independent Cancer Treatment. ACS Nano 2020. [PMID: 33290659 DOI: 10.1021/acsnano.0c08022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
637 Dai C, Lin F, Geng R, Ge X, Tang W, Chang J, Wu Z, Liu X, Lin Y, Zhang Z. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. Oncotarget. 2016;7:10332-10344. [PMID: 26871284 DOI: 10.18632/oncotarget.7243] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
638 Reddy VK, Shrestha DB, Gaire S, Mir WAY, Kassem M. Long-Term Favorable Outcome With Nivolumab in a Case of Advanced Non-Small Cell Lung Cancer: A Case Report. Cureus 2021;13:e18526. [PMID: 34765329 DOI: 10.7759/cureus.18526] [Reference Citation Analysis]
639 Luborsky JL, Barua A, Shatavi SV, Kebede T, Abramowicz J, Rotmensch J. Anti-Tumor Antibodies in Ovarian Cancer: ANTI-TUMOR ANTIBODIES IN OVARIAN CANCER. American Journal of Reproductive Immunology 2005;54:55-62. [DOI: 10.1111/j.1600-0897.2005.00287.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
640 D'Errico G, Machado HL, Sainz B Jr. A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet. Clin Transl Med 2017;6:3. [PMID: 28050779 DOI: 10.1186/s40169-016-0130-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
641 Jaimes EA. Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma. Seminars in Nephrology 2020;40:49-58. [DOI: 10.1016/j.semnephrol.2019.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
642 Martín P, Blanco-Domínguez R, Sánchez-Díaz R. Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer. Cell Mol Immunol 2021;18:919-35. [PMID: 33235388 DOI: 10.1038/s41423-020-00586-4] [Reference Citation Analysis]
643 Fang H, Guo Z, Chen J, Lin L, Hu Y, Li Y, Tian H, Chen X. Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. Nat Commun 2021;12:6742. [PMID: 34795289 DOI: 10.1038/s41467-021-27078-x] [Reference Citation Analysis]
644 Serrero G. Progranulin/GP88, A Complex and Multifaceted Player of Tumor Growth by Direct Action and via the Tumor Microenvironment. Adv Exp Med Biol 2021;1329:475-98. [PMID: 34664252 DOI: 10.1007/978-3-030-73119-9_22] [Reference Citation Analysis]
645 Orme JJ, Jazieh KA, Xie T, Harrington S, Liu X, Ball M, Madden B, Charlesworth MC, Azam TU, Lucien F, Wootla B, Li Y, Villasboas JC, Mansfield AS, Dronca RS, Dong H. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology 2020;9:1744980. [PMID: 32363112 DOI: 10.1080/2162402X.2020.1744980] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
646 Chang H, Liu B, Qi Y, Zhou Y, Chen Y, Pan K, Li W, Zhou X, Ma W, Fu C, Qi Y, Liu L, Gao Y. Blocking of the PD‐1/PD‐L1 Interaction by a D ‐Peptide Antagonist for Cancer Immunotherapy. Angew Chem Int Ed 2015;54:11760-4. [DOI: 10.1002/anie.201506225] [Cited by in Crossref: 140] [Cited by in F6Publishing: 131] [Article Influence: 20.0] [Reference Citation Analysis]
647 Xie Q, Wang L, Zheng S. Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis. Dis Markers 2020;2020:1817931. [PMID: 32724483 DOI: 10.1155/2020/1817931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
648 Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene. 2018;37:4639-4661. [PMID: 29765155 DOI: 10.1038/s41388-018-0303-3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 102] [Article Influence: 25.3] [Reference Citation Analysis]
649 Ryu R, Ward KE. Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects. Front Oncol 2018;8:277. [PMID: 30087855 DOI: 10.3389/fonc.2018.00277] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
650 Lynes J, Sanchez V, Dominah G, Nwankwo A, Nduom E. Current Options and Future Directions in Immune Therapy for Glioblastoma. Front Oncol 2018;8:578. [PMID: 30568917 DOI: 10.3389/fonc.2018.00578] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
651 Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, Varricchi G, Fallahi P, Antonelli A. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Pract Res Clin Endocrinol Metab 2020;34:101370. [PMID: 31983543 DOI: 10.1016/j.beem.2019.101370] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
652 Demuth C, Andersen MN, Jakobsen KR, Madsen AT, Sørensen BS. Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment. Oncotarget 2017;8:68221-9. [PMID: 28978110 DOI: 10.18632/oncotarget.19920] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
653 Rosenblatt J, Avigan D. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality? Blood 2017;129:275-9. [DOI: 10.1182/blood-2016-08-731885] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 10.6] [Reference Citation Analysis]
654 Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One. 2014;9:e89350. [PMID: 24586709 DOI: 10.1371/journal.pone.0089350] [Cited by in Crossref: 113] [Cited by in F6Publishing: 107] [Article Influence: 14.1] [Reference Citation Analysis]
655 Mitteldorf C, Berisha A, Tronnier M, Pfaltz MC, Kempf W. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma. J Cutan Pathol 2017;44:740-6. [PMID: 28569410 DOI: 10.1111/cup.12973] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
656 Deng Z, Teng YJ, Zhou Q, Ouyang ZG, Hu YX, Long HP, Hu MJ, Mei S, Lin FX, Dai XJ, Zhang BY, Feng T, Tian XF. Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(11): 1725-1740 [PMID: 34853646 DOI: 10.4251/wjgo.v13.i11.1725] [Reference Citation Analysis]
657 Augé H, Notarantonio AB, Morizot R, Quinquenel A, Fornecker LM, Hergalant S, Feugier P, Broséus J. Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome. Front Immunol 2020;11:594841. [PMID: 33381116 DOI: 10.3389/fimmu.2020.594841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
658 Kather JN, Berghoff AS, Ferber D, Suarez-Carmona M, Reyes-Aldasoro CC, Valous NA, Rojas-Moraleda R, Jäger D, Halama N. Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy. Oncoimmunology 2018;7:e1444412. [PMID: 29900054 DOI: 10.1080/2162402X.2018.1444412] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
659 Ampie L, Woolf EC, Dardis C. Immunotherapeutic advancements for glioblastoma. Front Oncol 2015;5:12. [PMID: 25688335 DOI: 10.3389/fonc.2015.00012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
660 Knol AC, Nguyen JM, Pandolfino MC, Denis MG, Khammari A, Dréno B. PD-L1 expression by tumor cell lines: A predictive marker in melanoma. Exp Dermatol 2018;27:647-55. [PMID: 29505109 DOI: 10.1111/exd.13526] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
661 Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006;177:8844-50. [PMID: 17142787 DOI: 10.4049/jimmunol.177.12.8844] [Cited by in Crossref: 140] [Cited by in F6Publishing: 138] [Article Influence: 9.3] [Reference Citation Analysis]
662 Chiloiro S, Russo F, Tartaglione T, Capoluongo ED. Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice. J Pers Med 2021;11:1026. [PMID: 34683167 DOI: 10.3390/jpm11101026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
663 Kongtawelert P, Wudtiwai B, Shwe TH, Pothacharoen P, Phitak T. Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer. Molecules 2020;25:E252. [PMID: 31936263 DOI: 10.3390/molecules25020252] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
664 Apetoh L, Ladoire S, Coukos G, Ghiringhelli F. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol 2015;26:1813-23. [PMID: 25922066 DOI: 10.1093/annonc/mdv209] [Cited by in Crossref: 126] [Cited by in F6Publishing: 126] [Article Influence: 18.0] [Reference Citation Analysis]
665 Ponomarev AV, Shubina IZ. Insights Into Mechanisms of Tumor and Immune System Interaction: Association With Wound Healing. Front Oncol 2019;9:1115. [PMID: 31709183 DOI: 10.3389/fonc.2019.01115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
666 Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, Fauci AS. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008;181:6738-46. [PMID: 18981091 DOI: 10.4049/jimmunol.181.10.6738] [Cited by in Crossref: 310] [Cited by in F6Publishing: 311] [Article Influence: 22.1] [Reference Citation Analysis]
667 Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treat Rev 2017;54:58-67. [PMID: 28214651 DOI: 10.1016/j.ctrv.2017.01.007] [Cited by in Crossref: 198] [Cited by in F6Publishing: 187] [Article Influence: 39.6] [Reference Citation Analysis]
668 Aris M, Barrio MM, Mordoh J. Lessons from cancer immunoediting in cutaneous melanoma. Clin Dev Immunol 2012;2012:192719. [PMID: 22924051 DOI: 10.1155/2012/192719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
669 Liu Y, Carlsson R, Ambjørn M, Hasan M, Badn W, Darabi A, Siesjö P, Issazadeh-Navikas S. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci 2013;33:14231-45. [PMID: 23986257 DOI: 10.1523/JNEUROSCI.5812-12.2013] [Cited by in Crossref: 75] [Cited by in F6Publishing: 56] [Article Influence: 8.3] [Reference Citation Analysis]
670 Abdou Y, Pandey M, Sarma M, Shah S, Baron J, Ernstoff MS. Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. Br J Clin Pharmacol 2020;86:1690-702. [PMID: 32323342 DOI: 10.1111/bcp.14316] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
671 Chen RQ, Liu F, Qiu XY, Chen XQ. The Prognostic and Therapeutic Value of PD-L1 in Glioma. Front Pharmacol 2018;9:1503. [PMID: 30687086 DOI: 10.3389/fphar.2018.01503] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
672 Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015-3029. [PMID: 20008522 DOI: 10.1084/jem.20090847] [Cited by in Crossref: 1184] [Cited by in F6Publishing: 1175] [Article Influence: 91.1] [Reference Citation Analysis]
673 Sood A, Cole D, Abdollah F, Eilender B, Roumayah Z, Deebajah M, Dabaja A, Alanee S. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. Curr Urol Rep 2018;19:68. [PMID: 29971696 DOI: 10.1007/s11934-018-0819-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
674 Farolfi A, Schepisi G, Conteduca V, Burgio SL, Lolli C, De Giorgi U. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. Expert Opin Drug Metab Toxicol 2016;12:1089-96. [PMID: 27450183 DOI: 10.1080/17425255.2016.1214713] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
675 Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, Weber WP, Soysal SD. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014;146:15-24. [PMID: 24842267 DOI: 10.1007/s10549-014-2988-5] [Cited by in Crossref: 302] [Cited by in F6Publishing: 320] [Article Influence: 37.8] [Reference Citation Analysis]
676 Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Ohshima K. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 2015;126:2193-201. [PMID: 26239088 DOI: 10.1182/blood-2015-02-629600] [Cited by in Crossref: 255] [Cited by in F6Publishing: 261] [Article Influence: 36.4] [Reference Citation Analysis]
677 Vasaturo A, Di Blasio S, Peeters DG, de Koning CC, de Vries JM, Figdor CG, Hato SV. Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Front Immunol 2013;4:417. [PMID: 24348481 DOI: 10.3389/fimmu.2013.00417] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.2] [Reference Citation Analysis]
678 Al-Jussani GN, Dabbagh TZ, Al-Rimawi D, Sughayer MA. Expression of PD-L1 using SP142 CDx in triple negative breast cancer. Ann Diagn Pathol 2021;51:151703. [PMID: 33454500 DOI: 10.1016/j.anndiagpath.2021.151703] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
679 Zhou Y, Luo GH. Porphyromonas gingivalis and digestive system cancers. World J Clin Cases 2019; 7(7): 819-829 [PMID: 31024953 DOI: 10.12998/wjcc.v7.i7.819] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
680 Zhu Z, Zhang H, Chen B, Liu X, Zhang S, Zong Z, Gao M. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages. Front Immunol 2020;11:588552. [PMID: